Document:

Form of Subscription Agreement

 EXHIBIT 4.2 
  
 SUBSCRIPTION AGREEMENT 
 SPECTRAL
MOLECULAR IMAGING, INC. 
  

	To:	Spectral Molecular Imaging, Inc. 

  
 This Subscription Agreement (this “Subscription Agreement”) is made by and between Spectral Molecular Imaging, Inc., a Nevada corporation
(the “Company”), and the undersigned prospective purchaser (the “Investor”) who is subscribing hereby for units (“Units”). Each Unit consists of one share of the Company’s common stock, $0.001
par value (sometimes referred to herein as the “Common Stock” and sometimes, the “Shares”) and one Common Stock purchase warrant (a “Warrant”). The Investor has received that certain Offering
Memorandum of the Company, dated July 5, 2005 and all exhibits and any supplements referred to therein (the “Memorandum”). Each Warrant is exercisable for one share of Common Stock at two dollars and fifty cents ($2.50) per
share for a period of three years. The Units are offered and sold in multiples of 20,000 Units for $1.00 per Unit. All information contained in this Subscription Agreement is after taking into effect a pending stock split of the Common Stock
described in the Memorandum. The Company may, in its discretion, sell a limited number of Units in multiples of 10,000 Units (for $10,000). The Units are offered to Accredited Investors (hereinafter defined) only. All funds received by the Company
pursuant to subscriptions for the Units will be deposited in a segregated bank account established by the Company. The Company is selling certain of the Units through finders, who will receive compensation described in the Memorandum in connection
with introducing purchasers of the Units to the Company. 
  
 In
consideration of the Company’s agreement to sell Units to the Investor upon the terms and conditions summarized in the Memorandum, the Investor or Company, as the case may be, agrees and represents as follows: 
  

	A.	SUBSCRIPTION. 

  
 1. The Investor hereby irrevocably subscribes for and agrees to purchase the number of Units indicated on the signature page hereof at a purchase price of
one dollar ($1.00) per Unit. The Investor encloses herewith a check payable to “Spectral Molecular Imaging, Inc.—Special Account” or has wire transferred to Bank of America, routing number 121000358, for deposit to the Company’s
account number 2151940728 in the amount of the purchase price of the Units for which the Investor is subscribing (the “Payment”). Subscription payments shall be made in U.S. funds, although the Company reserves the right to accept
payment in Canadian funds at the prevailing exchange rate at the time of the subscription at its sole discretion. 
  
 2. No Units will be sold unless (a) the Company receives and accepts subscriptions for at least 1,500,000 Units on or before August 31, 2005,
which date may be extended by the Company in its sole discretion to not later than September 30, 2005, and with the Offering continuing after receipt and acceptance of the subscriptions for at least 1,500,000 Units by the foregoing deadline
(the “Minimum Subscription Date”) until October 31, 2005 or such earlier date as the Company in its sole discretion shall determine (the “Provisional Offering Closing”), and (b) the Company completes the
Reorganization transaction with Patco Industries, Ltd., a Delaware corporation (the “Public Company”) in the manner described in the Memorandum (the “Reorganization”) within 30 days after the Provisional Offering
Closing (the “Final Closing”). The date of the Provisional Offering Closing shall be that date as shall be chosen by the Company. All subscription funds for the purchase of Units 

 
will be held in a segregated bank account of the Company (the “Escrow”) until immediately prior to the Reorganization. If subscriptions for
at least 1,500,000 Units are not received and accepted by the Minimum Subscription Date or if the Final Closing does not occur within 30 days after the Provisional Offering Closing, all funds held in the Escrow will be promptly returned to investors
without deduction therefrom or interest thereon. The sale of the Units will be deemed to have been completed immediately prior to the Final Closing, the Investor will become a stockholder of the Company immediately prior to the Final Closing, and
the name of such purchaser will be registered on the stock transfer books of the Company immediately prior to the Final Closing as the record owner of such Shares and Warrants. Immediately following the foregoing sale of Shares and Warrants, the
Shares and Warrants purchased by the Investor will be exchanged in the Reorganization for shares of the Public Company’s common stock and a warrant to purchase shares of the Public Company’s common stock, and the Public Company shall issue
to each subscriber whose subscription is accepted, (i) one or more stock certificates representing the shares of the Public Company’s common stock for which the Shares were exchanged in the Reorganization, and (ii) a Warrant
representing the purchaser’s right to purchase additional shares of the Public Company’s common stock. The Company may reject any subscription, in whole or in part, for any reason. The Payment (or, in the case of rejection of a portion of
the Investor’s subscription, the part of the Payment relating to such rejected portion) will be returned promptly if the Investor’s subscription is rejected in whole or in part. 
  

	B.	REGISTRATION. 

  
 As part of the Reorganization, the Public Company has agreed to file within 90 days following the completion of the Reorganization a registration
statement with the SEC to register all of the shares of Common Stock and all of the shares of Common Stock underlying the Warrants purchased by the Investor. The terms, conditions and limitations of the foregoing registration rights are set forth on
Appendix I to this Subscription Agreement. The Investor hereby agrees to be bound by the terms and conditions set forth on Appendix I. 
  

	C.	REPRESENTATIONS AND WARRANTIES. 

  
 C.1 Representations and Warranties by All Investors. 
  
 The Investor hereby represents and warrants to, and agrees with, the Company as follows: 
  
 1. The Investor has sufficient liquid assets to sustain a loss of the Investor’s entire investment. 
  
 2. The Investor represents that he is resident in the jurisdiction set forth
on the signature page to this Subscription Agreement and is an Accredited Investor as that term is defined in Regulation D (“Regulation D”) promulgated under the Securities Act of 1933, as amended (the “Act”), and
summarized in the Memorandum. The Investor also represents that he, either alone or with the Investor’s representative(s), has such knowledge and experience in financial and business matters that the Investor is capable of evaluating the merits
and risks of the investment in the Units. 
  
 3. The Investor
represents that he: (i) has adequate means of providing for his current financial needs and possible personal contingencies, and has no need for liquidity of his investment in the Company; (ii) can afford (a) to hold unregistered
securities for an indefinite period of time and (b) sustain a complete loss of the entire amount of the subscription; and (iii) has not made an overall commitment to investments which are not readily marketable that is so disproportionate
as to cause such overall commitment to become excessive. 
  

 2 

 4. The Investor’s Units are being purchased for the Investor’s own account, for investment
purposes only, not for the account of any other person, and not with a view to distribution, assignment or resale to others or to fractionalization in whole or in part. No other person has or will have a direct or indirect beneficial interest in the
Investor’s Units. The Investor will not sell, hypothecate or otherwise transfer the Investor’s Units unless: (a) there is an effective registration statement under the Act and applicable state securities laws covering any transaction
involving such securities, or (b) an exemption from the registration requirements of the Act and such state laws is available. 
  
 5. The Investor has been furnished with and has carefully read the Memorandum and is familiar with and understands the terms of the offering. In
evaluating the suitability of an investment in the Company, the Investor has not relied upon any representations or other information (whether oral or written) from the Company, other than as set forth in the Memorandum. With respect to the
Investor’s tax and other economic considerations involved in this investment, the Investor is not relying on the Company. The Investor has carefully considered and has, to the extent the Investor believes such discussion necessary, discussed
with the Investor’s professional legal, tax, accounting and financial advisors the suitability of an investment in the Units for the Investor’s particular tax and financial situation and has determined that the Units being subscribed for
by the Investor are a suitable investment for the Investor. 
  
 6.
The Company has made available to the Investor all documents and information that the Investor has requested relating to an investment in the Units. 
  
 7. The Investor has received, read, understands and is familiar with the Memorandum, including, without limitation, the “Risk Factors” section
contained therein and the exhibits attached thereto. 
  
 8. The
Investor confirms that the Company has made available to the Investor the opportunity to ask questions of, and receive answers from, representatives of the Company concerning the Offering, the Company and the activities of the Company, the Public
Company, and otherwise to obtain any additional information, to the extent that the Company possesses such information or could acquire it without unreasonable effort or expense, necessary to verify the accuracy of the information contained in the
Memorandum, and the Investor does not require any additional information concerning the foregoing. 
  
 9. The Investor recognizes that the Company is an early development stage company that has not generated any revenues to date and is not expected to have
any products commercially available for a number of years, if at all. In addition, the Public Company has not conducted any business operations in recent years. Therefore, the Investor realizes that an investment in the Company involves substantial
risks, including loss of the entire amount of such investment, and has taken full cognizance of and understands all of the risk factors relating to the purchase of the Units. 
  
 10. If this Subscription Agreement is executed and delivered on behalf of a partnership, corporation, trust or estate:
(i) such partnership, corporation, trust or estate has the full legal right and power and all authority and approval required: (a) to execute and deliver, or authorize execution and delivery of, this Subscription Agreement and all other
instruments executed and delivered by or on behalf of such partnership, corporation, trust or estate in connection with the purchase of its Units, (b) to delegate authority pursuant to a power of attorney, and (c) to purchase and hold such
Units; (ii) the signature of the party signing on behalf of such partnership, corporation, trust or estate is binding upon such partnership, corporation, trust or estate, and (iii) such partnership, corporation or trust has not been formed
for the specific purpose of acquiring such Units, unless each beneficial owner of such 

 3 

 
entity is qualified as an Accredited Investor within the meaning of Rule 501 (a) of Regulation D, and has submitted information substantiating such
individual qualification. 
  
 11. The Investor shall indemnify and
hold harmless the Company, and each officer, director or control person of any such entity, who is or may be a party or is or may be threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative, by reason of or arising from any actual or alleged misrepresentation or misstatement of facts or omission to represent or state facts made or alleged to have been made by the Investor to the Company or
omitted or alleged to have been omitted by the Investor, concerning the Investor or the Investor’s authority to invest or financial position in connection with the offering or sale of the Units, including, without limitation, any such
misrepresentation, misstatement or omission contained in the Questionnaire submitted by the Investor, against losses, liabilities and expenses for which the Company or any officer, director or control person of any such entity has not otherwise been
reimbursed (including, without limitation, attorneys’ fees, judgments, fines and amounts paid in settlement) actually and reasonably incurred by the Company or such officer, director or control person in connection with such action, suit or
proceeding. 
  
 C.2 Additional Representations and Warranties
by Canadian Residents. 
  
 1. The Investor, if resident in
either British Columbia or Alberta, hereby represents and warrants to, and agrees with, the Company: 
  
 that the Investor is purchasing as principal, or is deemed to be purchasing as principal under the Securities Act (British Columbia) (the
“B.C. Act”), and is an “accredited investor” as defined in Multilateral Instrument 45-103 Capital Raising Exemptions (“MI 45-103”) and the Investor has completed and executed the British Columbia and Alberta
Accredited Investor Certificate attached hereto as Appendix II and confirms the truth and accuracy of all statements made therein by the Investor. 
  
 2. If the Investor is a resident of, incorporated under or otherwise subject to the laws of the Province of Ontario, the Investor is an “accredited
investor” as that term is defined in Ontario Securities Commission Rule 45-501, and the Investor has completed and executed the Ontario Accredited Investor Certificate attached hereto as Appendix III to this Subscription Agreement and
confirms the truth and accuracy of all statements made therein by the Investor; 
  
 3. the Units and any securities of the Public Company acquired following the Reorganization will be subject to resale or transfer restrictions, including the following: 
  

	 	(i)	the Units or any Public Company securities will be subject to resale restrictions under applicable securities legislation; 

  

	 	(ii)	the Investor will not be able to resell, assign or otherwise dispose of the Units or any Public Company securities unless they are subsequently distributed under a prospectus or in
compliance with all applicable resale restrictions; 

  

	 	(iii)	the Company may be required to legend the certificates representing the Units or any Public Company securities regarding these and any other restrictions on resale; and

  

	 	(iv)	 the Company is under no obligation to qualify the resale of the Units or any Public Company securities under a prospectus, or assist the Investor in 

  

 4 

	 	 
complying with any exemption from the prospectus requirement or resale restrictions set out under applicable securities legislation.

  

	D.	UNDERSTANDINGS. 

  
 The Investor understands, acknowledges and agrees with the Company as follows: 
  
 1. This Subscription may be rejected, in whole or in part, by the Company, in its sole and absolute discretion, at any time
before the Final Closing, notwithstanding prior receipt by the Investor of notice of acceptance of the Investor’s Subscription. 
  
 2. This Subscription is and shall be irrevocable, except that the Investor shall have no obligations hereunder in the event that this Subscription is
rejected in full for any reason. 
  
 3. No Federal or state agency
has made any finding or determination as to the accuracy or adequacy of the Memorandum or as to the fairness of the terms of this offering for investment, nor any recommendation or endorsement of the Units. 
  
 4. The offering and sale of the Units is intended to be exempt from
registration under the Act by virtue of Section 4(2) of the Act, and Rule 506 thereunder, which is in part dependent upon the truth, completeness and accuracy of the statements made by the Investor herein and in the Questionnaire. 

 
 5. The Company currently is a private company whose shares have not been
registered with any governmental agency. In addition, the offer and sale of the Shares under the Memorandum have not been registered. Accordingly, the Common Stock contained in the Units will not be freely transferable. In the Reorganization, the
Company will exchange the Shares for shares of common stock of the Public Company. The shares of the Public Company’s stock that an Investor will receive in the Reorganization will also not be registered or freely transferable, and unless those
shares are registered sooner, cannot be publicly resold for at least one year after the date of the Reorganization. Although the Public Company will be required to file a registration statement within 90 days following the Final Closing to register
the Shares and shares of Common Stock issuable upon exercise of the Warrants, the Public Company may encounter delays in completing this registration and the Investor may have to bear the economic risk of his investment in the Units for an
indefinite period of time. Although the Public Company’s shares are eligible for trading on the OTC-Other Market, there may not be a significant market in such stock in the future. In addition, there can be no assurance that a regular and
established market will be developed and maintained for the securities upon completion of the Reorganization and this Offering. There can also be no assurance as to the depth or liquidity of any market for the Public Company’s common stock or
the prices at which holders may be able to sell the shares. 
  
 6.
If the Company decides to use any placement agents, each of the placement agents will receive compensation in connection with the offering and sale of the Units but none of them will guarantee or assume responsibility for the operation or possible
liability of the Company, and none of them will supervise or participate in the operation or management of the Company. 
  
 7. The Investor understands that, in connection with the Reorganization, the Company will conduct a limited due diligence investigation of the Public
Company, including a reasonable investigation of the Public Company’s assets and liabilities, management and operations. The Investor acknowledges that, notwithstanding the Company’s due diligence investigation, undiscovered liabilities
and other problems with the Public Company may subsequently arise that will affect the 

  

 5 

 
value of the shares of the Public Company’s securities that the Investor will receive following the Reorganization. The Investor acknowledges that in
making its investment in the Units it is not relying upon any due diligence investigation of the Company to detect the Public Company’s undisclosed liabilities or problems. 
  
 8. The Investor acknowledges that no general solicitation or general advertising (including, without limitation,
communications published in any newspaper, magazine or other broadcast) has been received by him and that no public solicitation or advertisement with respect to the offering of the Units has been made to him. 
  
 9. The Investor acknowledges that the information contained in the Memorandum
is confidential and non-public and agrees that all such information shall be kept in confidence by the Investor and neither used by the Investor for the Investor’s personal benefit (other than in connection with this Subscription) nor disclosed
to any third party for any reason; provided, however, that this obligation shall not apply to any such information that (i) is part of the public knowledge or literature and readily accessible at the date hereof, (ii) becomes part of the
public knowledge or literature and readily accessible by publication (except as a result of a breach of this provision) or (iii) is received from third parties (except third parties who disclose such information in violation of any
confidentiality agreements or obligations). The Investor acknowledges that the information contained in the Memorandum regarding the Reorganization is non-public information and is material in nature. The applicable provisions of the United States
Federal and state securities laws, particularly Rule 10b-5 promulgated under the Securities Exchange Act of 1934, as amended, prohibit the purchase or sale of publicly traded securities on the basis of material non—public information.
Accordingly, the Investor agrees not to purchase or sell shares of the Public Company until the Reorganization has been completed and has been fully disclosed to the public and the Securities and Exchange Commission. 
  
 10. IN MAKING AN INVESTMENT DECISION PURCHASERS MUST RELY ON THEIR OWN
EXAMINATION OF THE COMPANY AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THESE UNITS HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE OR FOREIGN SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING
AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THE MEMORANDUM OR THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. 
  
 11. THE UNITS (INCLUDING THE SHARES OF COMMON STOCK, WARRANTS AND WARRANT SHARES CONTAINED THEREIN) MAY NOT BE TRANSFERRED,
RESOLD OR OTHERWISE DISPOSED OF EXCEPT AS PERMITTED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES
ACT OF 1933 OR UNDER APPLICABLE STATE SECURITIES LAWS. PURCHASERS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. 
  
 12. FOR RESIDENTS OF ALL STATES. THE SECURITIES OFFERED HEREBY HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON
TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER 

  

 6 

 
SAID ACT AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. THE CERTIFICATES EVIDENCING THE SECURITIES SHALL BEAR A RESTRICTIVE LEGEND REFLECTING
THE FOREGOING AND REQUIRING THE TRANSFEROR TO PROVIDE AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY FOR ANY TRANSFER PURSUANT TO AN EXEMPTION UNDER THE ACT. INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS
INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. 
  
 13. ANY UNITS
PURCHASED BY RESIDENTS OF BRITISH COLUMBIA, ALBERTA OR ONTARIO WILL BE SUBJECT TO RESALE RESTRICTIONS IMPOSED UNDER THE SECURITIES LAWS OF THOSE PROVINCES AND MAY ONLY BE SOLD PURSUANT TO AN AVAILABLE EXEMPTION. 
  

	E.	MISCELLANEOUS. 

  
 1. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the Memorandum. All pronouns and any
variations thereof used herein shall be deemed to refer to the masculine, feminine, impersonal, singular or plural, as the identity of the person or persons may require. 
  
 2. Except as set forth in Section D.1 herein, neither this Subscription Agreement nor any provision hereof shall be waived,
modified, changed, discharged, terminated, revoked or canceled except by an instrument in writing signed by the party effecting the same against whom any change, discharge or termination is sought. 
  
 3. Notices required or permitted to be given hereunder shall be in writing
and shall be deemed to be sufficiently given when personally delivered or sent by registered mail, return receipt requested, addressed: (i) if to the Company, at 8591 Skyline Drive, Los Angeles, California 90046; or (ii) if to the
Investor, at the address for correspondence set forth in the Questionnaire, or at such other address as may have been specified by written notice given in accordance with this paragraph E.3. 
  
 4. Failure of the Company to exercise any right or remedy under this
Subscription Agreement or any other agreement between the Company and the Investor, or otherwise, or delay by the Company in exercising such right or remedy, will not operate as a waiver thereof. No waiver by the Company will be effective unless and
until it is in writing and signed by the Company. 
  
 5. This
Subscription Agreement shall be enforced, governed and construed in all respects in accordance with the laws of the State of California, as such laws are applied by California courts to agreements entered into and to be performed in California by
and between residents of California, and venue shall be in the federal and state courts located in Los Angeles, California. This Subscription Agreement shall be binding upon the Investor, the Investor’s heirs, estate, legal representatives,
successors and assigns and shall inure to the benefit of the Company, its successors and assigns. If any provision of this Subscription Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be
deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof that may prove invalid or unenforceable under any law shall not affect the validity or
enforceability of any other provision hereof. 
  
 6. The Investor
hereby irrevocably nominates, constitutes and appoints the President of the Company as his, her or its agent and true and lawful attorney to act on his, her or its behalf, whether in the best interest of the Investor or otherwise, with full power
and authority in his, her or its 

  

 7 

 
name, place and stead to execute, under seal or otherwise, swear to, acknowledge, deliver and file or record when, as and where required: 
  

	 	(i)	any waiver required under applicable legislation or the constating documents of the Company waiving the Investor’s right to subscribe for a pro-rata portion of any securities
allotted while the Company is not a reporting company; and 

  

	 	(ii)	any escrow or pooling agreement in respect of the Units that is imposed by any regulatory body having jurisdiction or that the Company agrees to in its sole discretion.

  
 The power of attorney granted herein is an
irrevocable power coupled with an interest and it shall survive the death, disability, mental infirmity, or bankruptcy of the Investor or the assignment by the Investor of the whole or any part of the interest of the Investor in the Units. The
Investor agrees to be bound by any representations made and actions taken by the Company pursuant to this power of attorney in accordance with the terms hereof and hereby waives any and all defences which may be available to the Investor to contest,
negate or disaffirm the action of the Company taken under this power of attorney. The Company, its directors, officers, employees, advisors and agents shall not be liable for any act done or omitted hereunder as attorney for the Investor. The
Investor indemnifies the Company, its directors, officers, employees, advisors and agents and holds them harmless against any loss, liability or expense arising out of, or in connection with, any actions taken pursuant to this power of attorney.

  
 7. This Subscription Agreement constitutes the entire
agreement between the parties hereto with respect to the subject matter hereof and may be amended only by a writing executed by both parties hereto. 
  

	F.	SIGNATURE. 

  
 The signature page of this Subscription Agreement is contained as part of the applicable Subscription Package, entitled “Signature Page,”
appearing after the Investor Questionnaire. 
  
 [Remainder of page
intentionally left blank] 
  

 8 

 INDIVIDUAL INVESTOR QUESTIONNAIRE 
  
 Investor Name:                                   
                                        
                                        
                                        
                                        
      
  

	To:	Spectral Molecular Imaging, Inc. 

  
 The information contained in this Questionnaire is being furnished in order to determine whether the Investor’s subscription in the accompanying
Subscription Agreement to purchase the Units described in the Memorandum may be accepted. (Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the attached Subscription Agreement.) 

 
 ALL INFORMATION CONTAINED IN THIS QUESTIONNAIRE WILL BE TREATED
CONFIDENTIALLY. The Investor understands, however, that the Company may present this Questionnaire to such parties as it deems appropriate if called upon to establish that the proposed offer and sale of the Units is exempt from registration under
the Act or meets the requirements of applicable state securities or “blue sky” laws. Further, the Investor understands that the offering is required to be reported to the Securities and Exchange Commission and to various state securities
or “blue sky” regulators. 
  

	I.	PLEASE INDICATE DESIRED TYPE OF OWNERSHIP OF UNITS. 

  

	 ̈	Individual or business entity 

	 ̈	Joint Tenants (rights of survivorship) 

	 ̈	Tenants in Common (no rights of survivorship) 

  

	II.	IF THE INVESTOR IS AN INDIVIDUAL, PLEASE CHECK ANY OF THE STATEMENTS 1-4 BELOW THAT APPLIES TO YOU. 

  

	 ̈  1.	I have an individual net worth* or joint net worth with my spouse in excess of $1,000,000. 

  

	 ̈  2.	I have had an individual income* in excess of $200,000 in each of 2003 and 2004 and I reasonably expect an individual income in excess of $200,000 for 2005.

  

	 ̈  3.	My spouse and I have had a joint income in excess of $300,000 in each of 2003 and 2004, and I reasonably expect a joint income in excess of $300,000 for 2005.

  

	 ̈  4.	I am a director or executive officer of Spectral Molecular Imaging, Inc. 

	*	For purposes of this Questionnaire, the term “net worth” means the excess of total assets over total liabilities. In determining income, an investor should add to
his or her adjusted gross income any amounts attributable to tax-exempt income received, losses claimed as a limited partner in any limited partnership, deductions claimed for depletion, contributions to IRA or Keogh retirement plan, alimony
payments and any amount by which income from long-term capital gains has been reduced in arriving at adjusted gross income. 

  

 9 

	III.	IF THE INVESTOR IS NOT AN INDIVIDUAL, CHECK THE APPROPRIATE BOX THAT APPLIES TO YOU. 

  

					
	 (i)
	  	 ̈	  	A bank (as defined in Section 3(a)(2) of the Act or savings and loan association (as defined in Section 3(a)(5) of the Act), whether acting in its individual or fiduciary
capacity.
			
	 (ii)
	  	 ̈	  	A broker-dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended.
			
	 (iii)
	  	 ̈	  	An insurance company (as defined in Section 2(a)(13) of the Act).
			
	 (iv)
	  	 ̈	  	An investment company registered under the Investment Company Act of 1940, or a business development company as defined in said Investment Act.
			
	 (v)
	  	 ̈	  	A Small Business Investment Company licensed by the U.S. Small Business Administration.
			
	 (vi)
	  	 ̈	  	A plan established and maintained by a state, its political subdivisions or any agency or instrumentality thereof, for the benefit of its employees, which plan has total assets in excess of
$5,000,000.
			
	 (vii)
	  	 ̈	  	An employee benefit plan within the meaning of Title I of the Employment Retirement Income Security Act of 1974 (“ERISA”), if the investment decision with respect to this investment is
made by a plan fiduciary (as defined in Section 3(21) of ERISA) which is either a bank, savings and loan association, insurance company or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000,
or if a self-directed plan, its investment decisions are made solely by persons who are accredited investors.
			
	 (viii)
	  	 ̈	  	A private business development company as defined in the Investment Advisors Act of 1940.
			
	 (ix)
	  	 ̈	  	A corporation, Massachusetts or similar business trust or partnership, or any tax exempt organization as defined in Section 501(c)(3) of the Internal Revenue Code, not formed for the
specific purpose of acquiring the Units, with total assets in excess of $5,000,000.
			
	 (x)
	  	 ̈	  	A trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Units, whose purchase is directed by a person who has such knowledge and experience in
financial and business matters that he/she is capable of evaluating the merits and risks of an investment in the Units.

  

	IV.	OTHER CERTIFICATIONS. 

  
 By signing the Signature Page, I certify the following: 
  

	 	(a)	that I am at least 21 years of age; 

  

	 	(b)	that my purchase of a Unit will be solely for my own account and not for the account of any other person (other than my spouse, if co-owner); and 

  

	 	(c)	that the name, residence address and social security or taxpayer identification number as set forth in this Questionnaire are true, correct and complete. 

 

 10 

 SPECTRAL MOLECULAR IMAGING, INC. 
 INDIVIDUAL SIGNATURE PAGE 
  
 Your signature on this Individual Signature Page evidences your agreement to be bound by the Questionnaire and the Subscription Agreement. 
  
 The Investor represents that (a) he/she has read and understands this Subscription Agreement, (b) the information contained in this
Questionnaire is complete and accurate and (c) he/she will telephone the Company immediately if any material change in any of this information occurs before the acceptance of his/her subscription and will promptly send the Company written
confirmation of such change. 
  
 TO BE COMPLETED BY THE INVESTOR:

  

	A.	Subscription Amount. 

  

			
	 Subscription:
	  	_______________ Shares
		
	 Subscription Price Per Unit
	  	U.S.$1.00
		
	 Subscription Funds:
	  	U.S.$________________

  
 The Company reserves the right to
accept payment in Canadian funds at the prevailing exchange rate in its sole discretion. 
  

	B.	Name and Address. The name and address (to establish the Investor’s jurisdiction of residence for the purpose of determining the applicable Securities Rules) of the
Investor is as follows: 

  

							
	
	 
	 Name

	
	 
	 Street Address

	
	 
	
	 
	 City, Province, Country, Postal Code

	
	 
	 Social Security or Tax I.D. Number

		
	 Email: 
	 	 
				
	 Phone: 
	 	 	 	 Fax: 
	 	 

  

	C.	Registration Instructions. The name and address of the person in whose name the Investor’s securities are to be registered is as follows (if the name and address is the
same as was inserted in paragraph B above, then insert “see B above”): 

  

							
	
	 
	 Name

	
	 
	 Street Address

	
	 
	
	 
	 City, Province, Country, Postal Code

  

 11 

	D.	Delivery Instructions. The name and address of the person to whom the certificates representing the Investor’s securities referred to in paragraph B above are to be
delivered is as follows (if the name and address is the same as was inserted in paragraph B or C above, then insert “see B above” or “see C above”, as the case may be): 

  

							
	
	 
	 Name

	
	 
	 Street Address

	
	 
	
	 
	 City, Province, Country, Postal Code

	
	 
	 Signature

	
	 
	Name and, if the purchase is other than in individual, the title of such person (Please Type or Print)
	
	 
	 Signature of Spouse if Co-owner

	
	 
	 Name of Spouse if Co-owner

	
	 
	 Date

  
 THE UNITS AND UNDERLYING
SECURITIES CONTAINED IN THE UNITS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED UNLESS THE SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND
PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 
  

 12 

 Spectral Molecular Imaging, Inc., a Nevada corporation, hereby accepts the foregoing subscription subject
to the terms and conditions hereof this          day of
                            , 2005. 
  

			
	 SPECTRAL MOLECULAR IMAGING, INC.

		
	 By:   
	 	 
	 Name:
	 	 
	 Its:
	 	 

  

 13 

 SUBSCRIPTION AGREEMENT 
  
 APPENDIX I 
  
 1. Certain Definitions. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the Subscription
Agreement to which this Exhibit is attached. As used in this Exhibit, the following terms shall have the following respective meanings: 
  
 “Commission” means the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.

  
 “Company” means Spectral Molecular Imaging,
Inc., a Nevada corporation. 
  
 “Exchange Act”
means the Securities Exchange Act of 1934, as amended, or any similar federal rule or statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 
  
 “Holder” and “Holders” means (i) the
Investor, (ii) any other person who purchased Units pursuant to the Memorandum, and (iii) any person holding Registrable Securities to whom the registration rights under any of the Subscription Agreements have been validly transferred.

  
 “Investor” means the subscriber listed in the
attached Subscription Agreement. 
  
 “Public
Company” means Patco Industries, Ltd., a Delaware corporation. 
  
 “Registrable Securities” means shares of (i) the Public Company’s Common Stock issued in exchange for the Company’s Common Stock issued as part of the Units; (ii) the Public Company’s Common Stock
that have been issued upon exercise or are issuable upon exercise of the Warrants assumed by the Public Company; and (iii) any Common Stock of the Public Company issued or issuable in respect of the foregoing shares of the Public Company’s
Common Stock upon any stock split, stock dividend, recapitalization or similar event; provided, however, that securities shall only be treated as Registrable Securities if and so long as they have not been registered or sold to or
through a broker or dealer or underwriter in a public distribution or a public securities transaction. 
  
 The terms “register,” “registered” and “registration” refer to a registration effected by preparing and
filing a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration statement. 
  
 “Registration Expenses” shall mean all expenses incurred by the Public Company in complying with Section 2.1, including without
limitation, all registration, qualification and filing fees, printing expenses, fees and disbursements of counsel for the Public Company, blue sky fees and expenses, the expense of any special audits incident to or required by any such registration
(but excluding the compensation of regular employees of the Public Company which shall be paid in any event by the Public Company). 
  
 “Rule 144” and “Rule 145” shall mean Rules 144 and 145, respectively, promulgated under the Securities Act, or
any similar federal rules thereunder, all as the same shall be in effect at the time. 
  
 “Securities Act” shall mean the federal Securities Act of 1933, as amended, or any similar federal rule or statute and the rules and regulations of the Commission thereunder, all as the same shall be
in effect at the time. 
  

 14 

 “Selling Expenses” shall mean all underwriting discounts and selling commissions
applicable to the securities registered by the Holders. 
  
 “Warrant” and “Warrants” means those Common Stock purchase warrants issued by the Company as part of the Units sold pursuant to the Memorandum. 
  
 2. Registration. 
  
 2.1      Registration Filing. 
  
 (a)      Filing for Registrable Securities. Within 90 days following the
Final Closing (as defined in the Memorandum), the Public Company shall file a registration statement with the Commission for the sale of all of the Registrable Securities. 
  
 (b)      Inclusion of Other Shares. The Public Company may, at its option,
include shares held by other stockholders of the Public Company in any such registration statement filed under this Section 2.1. 
  
 2.2      Expenses of Registration. All Registration Expenses incurred in connection with a
registration pursuant to Section 2.1 shall be borne by the Public Company; provided, however, that the Public Company shall have no obligation to pay or otherwise bear (i) any portion of the fees or disbursements of counsel
for the Holders in connection with the registration of their Registrable Securities, (ii) any portion of any underwriter’s commissions or discounts, expense allowance or fees or stock transfer taxes attributable to the Registrable
Securities being offered and sold by the Holders of Registrable Securities, or (iii) any of such expenses if the payment of such expenses by the Public Company is prohibited by the laws of a state in which such offering is qualified and only to
the extent so prohibited. Unless otherwise stated, all Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the Holders of such securities pro rata on the basis of the number of shares so registered or
proposed to be so registered. 
  
 2.3      Registration Procedures. In the case of the registration effected by the Public Company pursuant to this Exhibit, the Public Company will keep each Holder advised in writing as to the
initiation of such registration and as to the completion thereof. The Public Company will: 
  
 (a)      Prepare and file with the Commission a registration statement and such amendments and supplements as may
be necessary and use its commercially reasonable best efforts to cause such registration statement to become and remain effective until (i) the first anniversary following the date the registration statement is declared effective, or
(ii) all of the Registrable Securities included in the registration statement have been sold, whichever comes first, except that the Public Company shall be permitted to suspend the use of the registration statement during certain periods as
set forth below in this Section 2.3; 
  
 (b)      Furnish to the Holders participating in such registration and to the underwriters of the securities being registered such reasonable number of copies of the registration statement, preliminary prospectus,
final prospectus and such other documents as such underwriters may reasonably request in order to facilitate the public offering of such securities; 
  
 Notwithstanding the foregoing, the Public Company shall notify each Holder whose securities are included in a registration of the happening of any event
which makes any statement made in the registration statement or related prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or which requires the making of any changes in the

  

 15 

 
registration statement or prospectus so that, in the case of the registration statement, it will not contain an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the prospectus, it will not contain an untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. In such event, the Public Company may suspend use of the prospectus on written notice to each participating Holder, in
which case each participating Holder shall not dispose of Registrable Securities covered by the registration statement or prospectus until copies of a supplemented or amended prospectus are distributed to the participating Holders or until the
participating Holders are advised in writing by the Public Company that the use of the applicable prospectus may be resumed (the period of such suspension shall be a “Blackout Period”). The Public Company shall ensure that the use
of the prospectus may be resumed as soon as is reasonably practicable. The Public Company shall, upon the occurrence of any event contemplated by this paragraph, prepare a supplement or post-effective amendment to the registration statement or a
supplement to the related prospectus or any document incorporated therein by reference or file any other required document so that, as thereafter delivered to the purchasers of the Registrable Securities being sold thereunder, such prospectus will
not contain an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. In the event that the Public Company declares
one or more Blackout Periods, the one-year anniversary period set forth in Section 2.3(a) shall be extended by the number of days that constitute any such Blackout Periods. 
  
 2.4      Indemnification. 
  
 (a)      The Public Company will
indemnify each Holder, each of its officers and directors and partners, and each person controlling such Holder within the meaning of Section 12 of the Securities Act, with respect to which registration has been effected pursuant to this
Exhibit, against all expenses, claims, losses, damages and liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on any untrue statement
(or alleged untrue statement) of a material fact contained in any registration statement, prospectus, offering circular or other document, or any amendment or supplement thereto, incident to any such registration, or based on any omission (or
alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or any violation by the Public Company of the
Securities Act, the Exchange Act, state securities laws or any rule or regulation promulgated under such laws applicable to the Public Company in connection with any such registration, and the Public Company will reimburse each such Holder, each of
its officers and directors, and each person controlling such Holder, for any legal and any other expenses reasonably incurred, as such expenses are incurred, in connection with investigating, preparing or defending any such claim, loss, damage,
liability or action, provided that the Public Company will not be liable in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission or alleged untrue statement
or omission, made in reliance upon and in conformity with written information furnished to the Public Company by or on behalf of such Holder for use therein. 
  
 (b)      Each Holder will, if Registrable Securities held by such Holder are included in the securities as to
which such registration is being effected, indemnify the Public Company, each of its officers and directors, each person who controls the Public Company within the meaning of Section 15 of the Securities Act, each other holder of the Public
Company’s securities covered by such registration statement, and each such holder’s officers and directors and each person controlling such holder within the meaning of Section 15 of the Securities Act, against all claims, losses,
damages and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement, prospectus, offering circular or 

  

 16 

 
other document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading, or any violation by the Holder of the Securities Act, the Exchange Act, state securities laws or any rule or regulation promulgated under such laws applicable to the Holder, and will reimburse the Public Company, such other
holders, such officers, directors, or control persons for any legal or any other expenses reasonably incurred, as such expenses are incurred, in connection with investigating or defending any such claim, loss, damage, liability or action, but in the
case of the Public Company or the other holders or their officers, directors, or control persons, only to the extent that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement,
prospectus, offering circular or other document in reliance upon and in conformity with information furnished to the Public Company in writing by such Holder. Notwithstanding the foregoing, the liability of each Holder under this Section 2.4(b)
shall be limited to an amount equal to the net proceeds from the offering received by such Holder. A Holder will not be required to enter into any agreement or undertaking in connection with any registration under this Section 2 providing for
any indemnification or contribution on the part of such Holder greater than the Holder’s obligations under this Section 2.4(b). 
  
 (c)      Each party entitled to indemnification under this Section 2.4 (the “Indemnified
Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall
permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the
Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such party’s expense, and provided further that the failure of any Indemnified Party to give notice as provided
herein shall not relieve the Indemnifying Party of its obligations under this Exhibit unless the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend such action and provided further, that the
Indemnifying Party shall not assume the defense for matters as to which there is a conflict of interest or there are separate and different defenses. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the
consent of each Indemnified Party (whose consent shall not be unreasonably withheld), consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to
such Indemnified Party of a release from all liability in respect to such claim or litigation. 
  
 (d)      Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution
contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
  
 3.      Transfer of Rights. The rights
granted under Section 2 of this Exhibit may be assigned to any transferee or assignee in connection with any transfer or assignment by the Holder of such Holder’s Warrants or Registrable Securities, provided that: (i) such transfer is
otherwise effected in accordance with applicable securities laws and the terms of this Exhibit; (ii) written notice is promptly given to the Public Company; and (iii) such transferee or assignee agrees in writing to be bound by the
provisions of this Exhibit and by any other agreement reasonably necessary to ensure compliance with the Federal and state securities laws. 
  

 17 

 SUBSCRIPTION AGREEMENT 
  
 APPENDIX II 
  
 BRITISH COLUMBIA AND ALBERTA ACCREDITED INVESTOR CERTIFICATE 
  
 The Investor is an “accredited investor”, as such term is defined in Multilateral Instrument 45-103 – Capital Raising
Exemptions (“MI 45-103”) and, as at the time the subscription is accepted by SMI (“Closing”), the Subscriber will fall within one or more of the following categories (Please check one or more, as applicable): 

 

					
			
	 ̈	    	(a)	    	a Canadian financial institution, or an authorized foreign bank listed in Schedule III of the Bank Act (Canada),
			
	 ̈	    	(b)	    	the Business Development Bank of Canada incorporated under the Business Development Bank of Canada Act (Canada),
			
	 ̈	    	(c)	    	an association under the Cooperative Credit Associations Act (Canada) located in Canada or a central cooperative credit society for which an order has been made under subsection 473(1) of
that Act,
			
	 ̈	    	(d)	    	a subsidiary of any person or company referred to in paragraphs (a) to (c), if the person or company owns all of the voting securities of the subsidiary, except the voting securities required by
law to be owned by directors of that subsidiary,
			
	 ̈	    	(e)	    	a person or company registered under the securities legislation of a jurisdiction of Canada, as an adviser or dealer, other than a limited market dealer registered under the Securities
Act (Ontario) or Securities Act (Newfoundland and Labrador),
			
	 ̈	    	(f)	    	an individual registered or formerly registered under the securities legislation of a jurisdiction of Canada, as a representative of a person or company referred to in paragraph
(e),
			
	 ̈	    	(g)	    	the government of Canada or a jurisdiction of Canada, or any crown corporation, agency or wholly owned entity of the government of Canada or a jurisdiction of Canada,
			
	 ̈	    	(h)	    	a municipality, public board or commission in Canada,
			
	 ̈	    	(i)	    	any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any agency of that government,
			
	 ̈	    	(j)	    	a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a pension commission or similar regulatory authority of a jurisdiction of
Canada,
			
	 ̈	    	(k)	    	an individual who, either alone or with a spouse, beneficially owns, directly or indirectly, financial assets having an aggregate realizable value that before taxes, but net of any related
liabilities, exceeds $1,000,000,

  

 18 

					
	 ̈	    	(l)	    	an individual whose net income before taxes exceeded $200,000 in each of the two most recent years or whose net income before taxes combined with that of a spouse exceeded $300,000 in each of
the two most recent years and who, in either case, reasonably expects to exceed that net income level in the current year,
			
	 ̈	    	(m)	    	a person or company, other than a mutual fund or non-redeemable investment fund, that, either alone or with a spouse, has net assets of at least $5,000,000, and unless the person or company is
an individual, that amount is shown on its most recently prepared financial statements,
			
	 ̈	    	(n)	    	a mutual fund or non-redeemable investment fund that, in the local jurisdiction, distributes its securities only to persons or companies that are accredited investors,
			
	 ̈	    	(o)	    	a mutual fund or non-redeemable investment fund that, in the local jurisdiction, is distributing or has distributed its securities under one or more prospectuses for which the regulator has
issued receipts,
			
	 ̈	    	(p)	    	a trust company or trust corporation registered under the Trust and Loan Companies Act (Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction,
trading as a trustee or agent on behalf of a fully managed account,
			
	 ̈	    	(q)	    	a person or company trading as agent on behalf of a fully managed account if that person or company is registered or authorized to carry on business under the securities legislation of a
jurisdiction of Canada or a foreign jurisdiction as a portfolio manager or under an equivalent category of adviser or is exempt from registration as a portfolio manager or the equivalent category of adviser,
			
	 ̈	    	(r)	    	a registered charity under the Income Tax Act (Canada) that, in regard to the trade, has obtained advice from an eligibility adviser or other adviser registered to provide advice on the
securities being traded,
			
	 ̈	    	(s)	    	an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to in paragraphs (a) through (e) and paragraph (j) in form and function, or
			
	 ̈	    	(t)	    	a person or company in respect of which all of the owners of interests, direct or indirect, legal or beneficial, except the voting securities required by law to be owned by directors, are
persons or companies that are accredited investors.

  
 For the purposes hereof, the following
definitions are included for convenience: 
  
 “affiliate” means
an issuer connected with another issuer because 
  

	 	(a)	one of them is the subsidiary of the other, or 

  

	 	(b)	each of them is controlled by the same person or company; 

  
 “Canadian financial institution” means a bank, loan corporation, trust company, insurance company, treasury branch, credit union or caisse populaire
that, in each case, is authorized to carry on business in Canada or a jurisdiction, or the Confédération des caisses populaires et d’économie Desjardins du Québec; 
  

 19 

 “financial assets” means cash and securities; 
  
 “mutual fund” includes an issuer of securities that entitles the holder to
receive on demand, or within a specified period after demand, an amount computed by reference to the value of a proportionate interest in the whole or in a part of the net assets, including a separate fund or trust account, of the issuer of the
securities; 
  
 “securities legislation” means securities
legislation as such term is defined in National Instrument 14-101 – Definitions; 
  
 “subsidiary” means a person or corporation controlled by another person or corporation; and 
  
 “$” means Canadian Dollars for purposes of Appendix II and Appendix III
only. 
  
 The foregoing representation, warranty and certificate is true an
accurate as of the date of this certificate and will be true and accurate as of Closing. If any such representation, warranty or certificate shall not be true and accurate prior to Closing, the undersigned shall give immediate written notice of such
fact to the Issuer. 
  
 The undersigned has executed this Certificate as of the
         day of                     ,
200            . 
  

					
	 If a Corporation, Partnership or Other Entity:
	 	 	 	 If an Individual:

			
	  	 	 	 	  
	 Name of Entity
	 	 	 	 Signature

			
	  	 	 	 	  
	 Type of Entity
	 	 	 	 Print or Type Name

			
	  	 	 	 	  
	 Signature of Person Signing
	 	 	 	 
			
	  	 	 	 	  
	 Print or Type Name and Title of Person Signing
	 	 	 	 

  

 20 

 SUBSCRIPTION AGREEMENT 
  
 APPENDIX III 
  
 ONTARIO ACCREDITED INVESTOR CERTIFICATE 
  
 The undersigned has represented that the undersigned an “accredited investor” as defined in Rule 45-501 of the Ontario Securities Commission. The undersigned
has indicated below the categories which it, he or she satisfies. 
  
 The Investor
understands that the Company is relying on this information in determining to sell securities to the Investor in a manner exempt from the registration requirements of the Ontario Securities Act (the “Ontario Act”). 
  

						
	 ̈	 	  	(a)	  	a bank listed in Schedule I or II of the Bank Act (Canada), or an authorized foreign bank listed in Schedule III of that Act;
			
	 ̈	 	  	(b)	  	the Business Development Bank incorporated under the Business Development Bank Act (Canada);
			
	 ̈	 	  	(c)	  	a loan corporation or trust corporation registered under the Loan and Trust Corporations Act or under the Trust and Loan Companies Act (Canada), or under comparable legislation in any other
jurisdiction;
			
	 ̈	 	  	(d)	  	a co-operative credit society, credit union central, federation of caisses populaires, credit union or league, or regional caisse populaire, or an association under the Cooperative Credit
Associations Act (Canada), in each case, located in Canada;
			
	 ̈	 	  	(e)	  	a company licensed to do business as an insurance company in any jurisdiction;
			
	 ̈	 	  	(f)	  	a subsidiary of any company referred to in paragraph (a), (b), (c), (d) or (e), where the company owns all of the voting shares of the subsidiary;
			
	 ̈	 	  	(g)	  	a person or company registered under the Act or securities legislation in another jurisdiction as an adviser or dealer, other than a limited market dealer;
			
	 ̈	 	  	(h)	  	the government of Canada or of any jurisdiction, or any crown corporation, instrumentality or agency of a Canadian federal, provincial or territorial government;
			
	 ̈	 	  	(i)	  	any Canadian municipality or any Canadian provincial or territorial capital city;
			
	 ̈	 	  	(j)	  	any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction, or any instrumentality or agency thereof;
			
	 ̈	 	  	(k)	  	a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada) or a provincial pension commission or similar regulatory
authority;
			
	 ̈	 	  	(l)	  	a registered charity under the Income Tax Act (Canada);

  

 21 

						
	 ̈	 	  	(m)	  	an individual who beneficially owns, or who together with a spouse beneficially own, financial assets having an aggregate realizable value that, before taxes but net of any related liabilities,
exceeds $1,000,000;
			
	 ̈	 	  	(n)	  	an individual whose net income before taxes exceeded $200,000 in each of the two most recent years or whose net income before taxes combined with that of a spouse exceeded $300,000 in each of
those years and who, in either case, has a reasonable expectation of exceeding the same net income level in the current year;
			
	 ̈	 	  	(o)	  	an individual who has been granted registration under the Act or securities legislation in another jurisdiction as a representative of a person or company referred to in paragraph (g), whether
or not the individual’s registration is still in effect;
			
	 ̈	 	  	(p)	  	a promoter of the issuer or an affiliated entity of a promoter of the issuer;
			
	 ̈	 	  	(q)	  	a spouse, parent, grandparent or child of an officer, director or promoter of the issuer;
			
	 ̈	 	  	(r)	  	a person or company that, in relation to the issuer, is an affiliated entity or a person or company referred to in clause (c) of the definition of distribution in subsection 1(1) of the
Act;
			
	 ̈	 	  	(s)	  	an issuer that is acquiring securities of its own issue;
			
	 ̈	 	  	(t)	  	a company, limited partnership, limited liability partnership, trust or estate, other than a mutual fund or non-redeemable investment fund, that had net assets of at least $5,000,000 as
reflected in its most recently prepared financial statements;
			
	 ̈	 	  	(u)	  	a person or company that is recognized by the Commission as an accredited investor;
			
	 ̈	 	  	(v)	  	a mutual fund or non-redeemable investment fund that, in Ontario, distributes its securities only to persons or companies that are accredited investors;
			
	 ̈	 	  	(w)	  	a mutual fund or non-redeemable investment fund that, in Ontario, distributes its securities under a prospectus for which a receipt has been granted by the Director;
			
	 ̈	 	  	(x)	  	a managed account if it is acquiring a security that is not a security of a mutual fund or non-redeemable investment fund;
			
	 ̈	 	  	(y)	  	an account that is fully managed by a trust corporation registered under the Loan and Trust Corporations Act;
			
	 ̈	 	  	(z)	  	an entity organized outside of Canada that is analogous to any of the entities referred to in paragraphs (a) through (g) and paragraph (k) in form and function;
and
			
	 ̈	 	  	(aa)	  	a person or company in respect of which all of the owners of interests, direct or indirect, legal or beneficial, are persons or companies that are accredited investors;

  

 22 

 The statements made in this Appendix III are true. 
  
 DATED
                                    , 2005. 
  

	
	
	  
	Signature of Investor
	
	  
	Name of Investor
	
	  
	Address of the Investor

  

 23Assignment and License Agreement dated November 1, 2004

 EXHIBIT 10.1 
  
 ASSIGNMENT AND LICENSE AGREEMENT 
  
 This ASSIGNMENT AND LICENSE AGREEMENT (this “Agreement”) is dated as of November 1, 2004, and is between CHROMODYNAMICS, INC., a
Pennsylvania corporation (“CDI”), SPECTRAL MOLECULAR TECHNOLOGIES, INC., a Nevada corporation (“Spectral”), and Daniel L. Farkas, Miriam Farkas, Elliott Wachman and Jill Wachman (these four individuals, collectively, the
“Inventors”). 
  
 RECITALS 
  
 WHEREAS, CDI is the exclusive licensee of the technology described on
Exhibit A attached hereto (the “CMU Technology”) pursuant to that certain License Agreement (the “CMU License Agreement”), dated as of June 25, 1998, between Carnegie Mellon University (“CMU”) and CDI; and

  
 WHEREAS, the Inventors are the inventors of and own all right,
title and interest in and to the spectral/hyperspectral endoscopic system, utilizing an acousto-optic tunable filter (AOTF) based implementation, described on Exhibit B attached hereto (the “Endoscopic Invention”); and 

 
 WHEREAS, Spectral is a start-up corporation that has not yet raised any
capital, and Daniel L. Farkas is the Chairman and will be a shareholder of Spectral; and 
  
 WHEREAS, Spectral desires to license the CMU Technology and receive an assignment of the Endoscopic Invention on the terms and conditions set forth herein; and 
  
 WHEREAS, CDI and the Inventors are willing to have CMU directly license the
CMU Technology to Spectral or have CDI sublicense the CMU Technology to Spectral and have the Inventors assign the Endoscopic Invention to Spectral on the terms and conditions set forth herein. 
  
 NOW, THEREFORE, the parties agree as follows: 
  
 ARTICLE 1 
 DEFINITIONS 
  
 “Affiliate” means any person, firm, corporation (including, without limitation, service corporation and professional corporation), partnership (including, without limitation, general partnership, limited partnership and limited
liability partnership), limited liability company, joint venture, business trust, association or other entity that now or in the future, directly or indirectly, controls, is controlled by or is under common control with a party. For purposes of the
foregoing, “control” means, with respect to: (a) a corporation, the ownership, directly or indirectly, of greater than fifty percent (50%) of the voting power to elect the directors thereof; and (b) any other entity,
managerial control by virtue of a written agreement or otherwise. 
  
 “CMU Patent Rights” means all valid claims in all patent applications, and all continuing and divisional patent applications, continuations-in-part, divisionals, prolongations and reissue applications claiming priority to such
applications, and all patents issuing therefrom or 
  
 Portions marked with {***}
have been omitted pursuant to a Request for Confidential Treatment and were filed separately with the Commission. 

 subsequent improvements thereto, whether U.S. or foreign, which at any time may be granted, relating to the CMU
Technology. 
  
 “CMU Product” means any product that,
but for this Agreement, the manufacture, use or sale of which would constitute an infringement of the unexpired CMU Patent Rights. 
  
 “Endoscopic Patent Rights” means all valid claims in all patent applications, and all continuing and divisional patent applications,
continuations-in-part, divisionals, prolongations and reissue applications claiming priority to such applications, and all patents issuing therefrom, or subsequent improvements thereto, whether U.S. or foreign, which at any time may be granted
relating to the Endoscopic Invention. 
  
 “Endoscopic
Product” means any product that, but for this Agreement, the manufacture, use or sale of which would constitute an infringement of the unexpired Endoscopic Patent Rights. 
  
 “Default” means the breach of a material term of this Agreement. 
  
 “Fiscal Quarter” means each period of three months ending on
March 31, June 30, September 30 and December 31. 
  
 “Net Sales” means the total gross revenues actually received by Spectral or its Affiliates or their licensees or sublicensees from the sales of Products to Third Parties, less deductions for the following,
to the extent actually paid or allowed with respect to such sales: 
  
 (a) sales and excise taxes and duties (including import duties) paid or allowed by a selling party and any other governmental charges imposed upon the manufacture or sale of the Product, after giving effect to any rebates or refunds
relating to such taxes or duties received by Spectral; and 
  
 (b)
normal and customary trade, quantity and cash discounts (up to the amount normal and customary for early payment of invoices); and 
  
 (c) allowances, chargebacks and credits to Third Parties on account of rejected, damaged, or returned Products; and 
  
 (d) outbound transportation prepaid or allowed. 
  
 If (i) a Product is sold by Spectral or an Affiliate or their licensees
or sublicensees as one of a number of items without a separate price; (ii) the consideration for the Product includes any non-cash element; or (iii) the Product is transferred by Spectral or an Affiliate or their licensees or sublicensees
in any manner other than an invoiced sale (excluding contributions of Products to governmental or private organizations), the Net Sales price applicable to any such transaction will be deemed to be Spectral’s average Net Sales price for the
Product at that time in the relevant jurisdiction. Net Sales shall not include any amounts received for microscopes or other equipment sold in conjuction with Products that do not include the CMU Technology or Endoscopic Invention. 
  

 2 

 “Products” means Endoscopic Products and CMU Products. 
  
 “Term” is defined in Section 9.1. 
  
 “Third Party” means any person or entity other than CDI, Spectral,
the Inventors and their respective Affiliates. 
  
 ARTICLE 2

 GRANT OF RIGHTS 
  
 Section 2.1 Endoscopic Invention. The Inventors hereby assign and transfer to Spectral all of their right, title and interest in and to the
Endoscopic Invention and Endoscopic Patent Rights, free and clear of all liens, claims or encumbrances. CDI hereby acknowledges and consents to the foregoing assignment of the Endoscopic Invention and Endoscopic Patent Rights and releases and
assigns to Spectral any claims to or rights it may now or in the future have in the Endoscopic Invention and Endoscopic Patent Rights. The Inventors and CDI hereby jointly and severally agree to indemnify and hold harmless Spectral and its
shareholders against any claim made by CDI, any CDI shareholder or CMU based on the assignment pursuant to this Section 2.1. 
  
 Section 2.2 CMU Technology. CDI and the Inventors shall use their commercially reasonable best efforts to assist Spectral, at Spectral’s cost
and expense, in acquiring a direct, exclusive, worldwide license from CMU of the CMU Technology for use in developing and commercializing the Endoscopic Invention and otherwise for use in developing and commercializing dermoscopic applications and
devices and other imaging applications and devices for ultimate clinical use (collectively, the “Endoscopic Applications”). If Spectral is unable to obtain a direct, exclusive, worldwide license from CMU of the CMU Technology on or before
January 15, 2005, then CDI shall, subject to the terms of this Agreement, grant as of that date to Spectral an exclusive, worldwide sublicense to develop, manufacture, market, distribute, import, offer for sale and sell CMU Products, both on
its own and through one or more Affiliates, distributors and sublicensees, for the Endoscopic Applications; provided, however, that the sublicense to the CMU Technology, if granted by CDI to Spectral pursuant to this Section 2.2, will
terminate immediately upon the termination of the CMU License Agreement. Upon any sublicense to Spectral under this Section 2.2, Spectral shall assume, along with CDI, all of CDI’s obligations under the CMU License Agreement. CDI shall use
its commercially reasonable best efforts to maintain the CMU License Agreement in full force and effect and shall promptly notify Spectral in writing of any prospective or actual default thereunder by CDI. CDI shall also use its commercially
reasonable best efforts to obtain CMU’s agreement to enter into a direct license with Spectral having the same terms and conditions as the CMU License Agreement in the event that agreement is terminated by CMU due to a default by CDI. Spectral
may sublicense the rights granted in this Section 2.2; provided, however, that Spectral shall obtain CDI’s prior written consent, which consent shall not be unreasonably withheld or delayed, in the case of any sublicense to an
entity other than an Affiliate of Spectral. 
  

 3 

 ARTICLE 3 
 DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS 
  
 Section 3.1 Development of Products. Spectral shall, at its sole cost and expense, use commercially reasonable efforts to develop and commercialize the Products, in the area of medical applications and such
other areas, if any, as Spectral in its sole discretion shall determine. Spectral shall provide a written report to the Inventors every year during the Term, stating in reasonable detail all significant progress achieved and material difficulties
encountered since the last such report in the development of Products. The parties acknowledge that (i) the Endoscopic Invention and the CMU Technology are at an early stage of development and are not yet ready for clinical development, and
(ii) Spectral will need to raise significant capital before it can carry out substantial development activities with respect to the Endoscopic Invention and the CMU Technology. CDI and the Inventors acknowledge that Spectral intends to own,
acquire and develop other technologies in the spectral or molecular imaging field having medical or other applications and that these technologies shall not be subject to the terms of this Agreement. 
  
 Section 3.2 Manufacturing of Products. Spectral shall, at its sole
cost and expense, manufacture, or have manufactured, the Products. 
  
 Section 3.3 Marketing of Products. Spectral will control and make all decisions regarding the strategy and tactics of marketing, selling and otherwise commercializing the Products, including, without limitation, the method of sales
and distribution, organization and management of sales and marketing, packaging and labeling, and other terms and conditions for such sales and marketing. Spectral may designate and appoint one or more Third Parties to act as its agent in connection
with the marketing, sale and distribution of the Products. 
  
 Section 3.4 SBIR/NIH Grant. Elliot Wachman and Daniel L. Farkas are co-investigators (PI and co-PI) under a CDI-sponsored SBIR/NIH $100,000 Phase I grant for endoscopy research related to the Endoscopic Invention and the CMU
Technology. Upon successful completion of the Phase I research project, CDI shall permit Spectral to join it as co-applicant organization and shall use its commercially reasonable efforts to obtain a Phase II SBIR/NIH grant for additional research
in this area, or shall allow Spectral to become the lead applicant organization in case CDI becomes ineligible for submitting an SBIR application. 
  
 Section 3.5 Elliott Wachman Consulting. Elliott Wachman shall make reasonable efforts to be available to provide off-site consulting services to
Spectral, as Spectral may reasonably request from time to time, to assist Spectral in performing its obligations under this Agreement. The terms and conditions, including the scope of services and compensation, will be negotiated in good faith by
Spectral and Elliott Wachman, who will in no event be required to provide, or be requested by Spectral to provide, more than 20 days per year of consulting services hereunder. Spectral shall have no obligation to retain Elliott Wachman to provide
any of the foregoing services. 
  

 4 

 ARTICLE 4 
 PAYMENTS; ACCOUNTING 
  
 Section 4.1 Reimbursement of Endoscopic Invention Legal Fees. Spectral shall, within thirty (30) days of the date hereof, (i) pay to CDI (who shall allocate a portion of this payment to the Inventors as the Inventors and
CDI shall agree among them) five thousand five hundred twenty-two dollars ($5,522) for legal fees incurred in connection with the Endoscopic Invention, and (ii) pay to Ed Penkoske, Esq., on behalf of CDI and the Inventors, the sum of two
thousand four hundred thirty-one dollars and twenty-five cents ($2,431.25) plus such additional amounts incurred or billed by Mr. Penkoske in connection with the Endoscopic Patent Rights through the date of execution of this Agreement;
provided, however, that Spectral’s obligations under clause (ii) of this Section 4.1 will in no event exceed three thousand two hundred seventy-eight dollars ($3,278) and CDI shall promptly pay any remaining amounts owing to
Mr. Penkoske for that period. 
  
 Section 4.2 Spectral
Financing. Spectral shall use its commercially reasonable diligence to obtain four hundred thousand dollars ($400,000) or more in aggregate financing from all sources (including, without limitation, debt, equity financing, financing in kind and
grants from governmental or other agencies) within eighteen (18) months from the date of this Agreement. Upon raising an aggregate of two hundred fifty thousand dollars ($250,000) or more, Spectral shall promptly pay (i) sixteen thousand
two hundred dollars ($16,200) to the Inventors (to be divided equally among them), and (ii) forty thousand dollars ($40,000) to CDI or, at Spectral’s election, to third parties to purchase equipment, in either case to be used solely to
conduct spectral endoscopy-related research activities in support of the Phase II SBIR grant described in Section 3.4. 
  
 Section 4.3 Endoscopic Sublicensing Fees. Spectral shall pay to the Inventors {***} for each license of the Endoscopic Invention granted by
Spectral to any Third Party. Spectral shall pay all amounts due to the Inventors under this Section 4.3 within thirty (30) days of the date Spectral receives the underlying sublicensing fees from the Third Party sublicensee. All payments
made by Spectral to the Inventors under Article 4 will be paid in equal amounts to the Inventors and will be subject to offset by Spectral for all amounts that Spectral is required to pay to Third Parties or expenses incurred by Spectral in
defending against any claim by a Third Party of ownership of the Endoscopic Invention or infringement by the Endoscopic Invention or that are otherwise owed by the Inventors to Spectral pursuant to the terms of this Agreement. 
  
 Section 4.4 Royalties. 
  
 (a) Spectral shall pay to the Inventors {***}. Spectral
shall, in the case of a direct license with CMU, pay a total of not more than {***} to CMU and CDI, with CDI to receive {***}. Spectral shall, in the case of a sublicense from CDI, pay CDI {***}. 
  
 (b) Spectral shall pay to CDI or the Inventors, as the case
may be, the royalties payable under Section 4.4 no later than thirty (30) days following the end of each Fiscal Quarter. All payments must be accompanied by a written report showing for the Fiscal Quarter for which the royalty payment
applies: (i) the Net Sales of each Product (along with a detailed description of the calculation thereof); and (ii) the royalties payable pursuant to Section 4.4. 

  

 5 

 
With respect to Net Sales of Products that are made in a currency other than the U.S. Dollar, Spectral shall state the Net Sales and royalties payable
hereunder in the domestic currency of the country in which the Net Sales were made, together with the U.S. Dollar equivalent, based on the exchange rate specified by Section 4.4(c). 
  
 (c) In making currency conversions pursuant to
Section 4.4(b), Spectral shall use the average of the U.S. Dollar equivalent exchange rate as published in The Wall Street Journal for the first and last business day of the applicable Fiscal Quarter. 
  
 (d) Spectral shall use commercially reasonable efforts to
require each licensee of the Endoscopic Invention or sublicensee of CMU Technology to pay directly to CDI, or the Inventors, as the case may be, royalties on Net Sales of the Products by such licensee or sublicensee, which royalties will be computed
and payable in accordance with this Section 4.4. Spectral and each licensee of the Endoscopic Invention or sublicensee of the CMU Technology will be jointly and severally liable for royalties on Net Sales of the Products by such licensee or
sublicensee. 
  
 (e) Spectral shall have no
obligation to make any payments to CDI (or any successor in interest to CDI) under Article 4 that would otherwise be payable with respect to any period after CDI sells all or substantially all of its assets or merges or completes any other
similar transaction in which its current shareholders own less than 50% of the surviving entity. However, each of Spectral’s obligations to the Inventors under Article 4 shall remain unchanged. 
  
 Section 4.5 Confidential Financial Information. CDI and the Inventors
shall treat all financial information pertaining to this Agreement as confidential and shall not disclose any of this information to any third party. 
  
 ARTICLE 5 
 PATENTS 
  
 Section 5.1 Patent Filings, Prosecution and Maintenance. Spectral
shall use commercially reasonable efforts in the filing, prosecution and maintenance of the Endoscopic Patent Rights for the U.S. and such other territories as Spectral shall determine in its sole discretion, using patent counsel of its choice.
Spectral shall furnish to the Inventors in a timely manner copies of all material documents relating to, and shall consult with the Inventors concerning, the preparation, filing, prosecution and maintenance of the Endoscopic Patent Rights. Spectral
shall provide the Inventors with copies of any proposed submissions in connection with the prosecution and maintenance of the Endoscopic Patent Rights for review and comment prior to filing, and shall take into account the Inventors’ comments
related thereto and incorporate or act on such comments to the extent deemed appropriate and reasonable by Spectral and its patent counsel. The Inventors shall treat as confidential all information provided to them for Spectral under this
Section 5.1 and shall not disclose any of this information to any third party. 
  
 Section 5.2 Infringement Actions by Third Parties. If CDI, the Inventors, Spectral or their respective Affiliates, or Spectral’s licensees, distributors or customers are sued or threatened with suit by a
Third Party for infringement of a Third Party patent or for 

  

 6 

 
misappropriation of any Third Party know-how, proprietary, technical or confidential information because of Spectral’s use or license of the Endoscopic
Invention or the development, manufacture or commercialization of Endoscopic Products (each, an “Infringement Action”), such party shall promptly notify the other parties in writing. The Inventors will have the first right, but not the
obligation, to defend each Infringement Action, using counsel reasonably acceptable to Spectral. The Inventors shall notify Spectral in writing, within thirty (30) days of becoming aware of an Infringement Action, whether or not the Inventors
will defend the Infringement Action. If the Inventors elect not to defend the Infringement Action, Spectral shall defend the Infringement Action, in which case the Inventors shall provide all assistance reasonably requested by Spectral, at no cost
to Spectral. The party defending an Infringement Action shall take into account the other party’s comments relating to such Infringement Action to the extent reasonable. No party may settle or consent to an adverse judgment with respect to an
Infringement Action without the express written consent of the other parties (such consent not to be unreasonably withheld or delayed). 
  
 Section 5.3 Enforcement of Endoscopic Patent Rights. 
  
 (a) In the event that CDI, the Inventors or Spectral becomes aware of actual or threatened infringement of the Endoscopic Patent Rights,
such party shall promptly notify the other parties in writing of such infringement and supply the other party with all evidence possessed by the notifying party pertaining to and establishing said infringement. The Inventors will have the first
right, but not the obligation, to bring an infringement action against the alleged infringing party, using counsel reasonably acceptable to Spectral. If the Inventors do not commence an infringement action within thirty (30) days of the date
the Inventors become aware of the alleged infringement, Spectral shall have the right to bring an infringement action against the alleged infringing party. The party conducting the action will have full control over its conduct, including the
settlement thereof; provided, however, that no settlement of an action will be made without the consent of the other party (which consent shall not be unreasonably withheld or delayed) if such settlement would adversely affect such party.

  
 (b) All monies recovered upon the final
judgment or settlement recovered pursuant to this Section 5.3 will be divided among the parties as follows after the party conducting the litigation first receives its legal fees and other third party costs incurred in conducting such
litigation: (i) the Inventors will be entitled to an amount equal to the remaining amount of the final judgment or settlement multiplied by {***}, and (ii) Spectral will be entitled to the balance of the judgment or settlement. 

 
 ARTICLE 6 
 CONFIDENTIALITY 
  
 Section 6.1 Confidentiality and Non-Use Obligations. 
  
 (a) During the Term and for five (5) years thereafter without regard to the means of termination, no party to this Agreement may, for
any purpose other than the purpose of this Agreement, reveal or disclose to any third party information and materials disclosed by another party and marked as confidential or for which the receiving party knows or has reason to 

  

 7 

 
know are or contain trade secrets or other proprietary information of the disclosing party (“Confidential Information”) without first obtaining the
written consent of the disclosing party. 
  
 (b)
Each party shall take all reasonable precautions to prevent the use or disclosure of another party’s Confidential Information without first obtaining the written consent of the disclosing party. 
  
 (c) The restrictions on the disclosure and use of
Confidential Information contained in this Article 6 do not apply to any information that: 
  
 (i) can be demonstrated by the recipient to have already been in its possession at the time of disclosure by the disclosing party;

  
 (ii) is or later becomes available to the
public, as evidenced by documents which are generally available; provided that such availability is not caused by a breach of this Article 6; 
  
 (iii) is received from a Third Party having legitimate possession thereof and the independent legal right to make such disclosure;

  
 (iv) is developed by the receiving party
entirely without reference to, or use of, Confidential Information; or 
  
 (v) is required to be disclosed by law or government regulation. 
  
 Section 6.2 Press Releases and Public Announcements. No party may issue any press release or other publicity materials, or make any public
presentation with respect to the specific terms or conditions of this Agreement without the prior written consent of the other parties (such consent not to be unreasonably withheld or delayed). The restrictions contained in this Section 6.2 do
not apply to disclosures that are limited to a general disclosure of the existence of this Agreement and the parties to this Agreement or disclosures required by law or regulation; provided that the disclosing party gives the other parties
reasonable advance notice of the proposed disclosure that is legally required, including the text thereof. 
  
 ARTICLE 7 
 REPRESENTATIONS AND WARRANTIES 
  
 Section 7.1 CDI’s Representations and Warranties. CDI represents
and warrants to Spectral that: 
  
 (a) CDI is a
corporation duly organized, validly existing, and in good standing under the laws of the State of Pennsylvania and has full power to own its properties and conduct the business presently being conducted by it, and is duly qualified to do business
in, and is in good standing under, the laws of all states and nations in which its activities or assets require such status, except in any case where the failure to be so qualified and in good standing would not be material. 
  

 8 

 (b) CDI has full right, power and authority to perform its obligations pursuant to this
Agreement, and this Agreement and the transactions contemplated hereby have been duly and validly authorized by all necessary action on the part of CDI. This Agreement has been duly and validly executed by CDI. Upon execution and delivery of this
Agreement, it will be the valid and binding obligation of CDI, enforceable in accordance with its terms, subject to equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditor’s
rights and remedies generally. 
  
 (c) The
execution, delivery and performance of this Agreement do not, and the consummation of the transactions contemplated herein will not, violate any law, rule, regulation, order, judgment or decree binding on CDI or result in a breach of any term of the
certificate of incorporation or by-laws of CDI or any contract, agreement or other instrument to which CDI is a party, except in each case to an extent not material. No authorization is required by CDI for the execution, delivery, or performance of
this Agreement by CDI. 
  
 (d) To the best of
CDI’s knowledge, the CMU License Agreement is in full force and effect and is a valid, binding and enforceable agreement between CDI and CMU; CDI currently is in compliance with all of the material terms of the CMU License Agreement; and CDI
has not received any notice of default from CMU under the CMU License Agreement. 
  
 (e) CDI and the Inventors are the sole owners of the entire right, title and interest in and to the Endoscopic Invention and no other
person or entity has any license, claim or other right or interest in or to the Endoscopic Invention. 
  
 (f) To the best of CDI’s knowledge, neither the CMU Technology nor the Endoscopic Invention infringes, misappropriates or otherwise
conflicts with any intellectual property or other rights of any third party and CDI has not received notice from any third party of any such claim. 
  
 (g) CDI is not aware of any infringement or misappropriation of the CMU Technology or the Endoscopic Invention by any third party.

  
 (h) There are no judicial, arbitral,
regulatory or administrative proceedings or investigations, claims, actions or suits relating to the CMU Technology or the Endoscopic Invention pending against or, to the best of CDI’s knowledge, threatened against CDI or its Affiliates in any
court or by or before any governmental body or agency and, to the best of CDI’s knowledge, no such judicial, arbitral, regulatory or administrative proceedings or investigations, actions or suits have been threatened against CDI or its
Affiliates. 
  
 (i) CDI follows reasonable
commercial practices common in the industry to protect its proprietary and confidential information, including requiring its employees, consultants and agents to be bound in writing by obligations of confidentiality and non-disclosure, and requiring
its employees, consultants and agents to assign to it any and all inventions and discoveries discovered by such employees, consultants and/or agents made within the scope of and during their employment, and only disclosing proprietary and
confidential information to Third Parties pursuant to written confidentiality and non-disclosure agreements. 
  

 9 

 Section 7.2 Representations and Warranties of Spectral. Spectral represents and warrants to CDI
and each Inventor that: 
  
 (a) Spectral is a
corporation duly organized, validly existing and in good standing under the laws of the State of Nevada and has full corporate power to own its properties and conduct the business presently being conducted by it, and is duly qualified to do business
in, and is in good standing under, the laws of all states in which its activities or assets require such status, except in any case where the failure to be so qualified and in good standing would not be material. 
  
 (b) Spectral has full corporate right, power and authority
to perform its obligations pursuant to this Agreement, and this Agreement and the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action on the part of Spectral. This Agreement has been duly and
validly executed by Spectral. Upon execution and delivery of this Agreement, it will be the valid and binding obligation of Spectral enforceable in accordance with its terms, subject to equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and similar laws affecting creditor’s rights and remedies generally. 
  
 (c) The execution, delivery and performance of this Agreement do not, and the consummation of the transactions contemplated herein will
not, violate any law, rule, regulation, order, judgment or decree binding on Spectral or result in a breach of any term of the certificate of incorporation or by-laws of Spectral or any contract, agreement or other instrument to which Spectral is a
party, except in each case to an extent not material. No authorization is required by Spectral for the execution, delivery, or performance of this Agreement by Spectral. 
  
 (d) Spectral follows reasonable commercial practices common in the industry to protect its proprietary and
confidential information, including requiring its employees, consultants and agents to be bound in writing by obligations of confidentiality and nondisclosure, and requiring its employees, consultants and agents to assign to it any and all
inventions and discoveries discovered by such employees, consultants and/or agents made within the scope of and during their employment, and only disclosing proprietary and confidential information to Third Parties pursuant to written
confidentiality and nondisclosure agreements. 
  
 Section 7.3
Inventors’ Representations and Warranties. Each Inventor represents and warrants to Spectral that: 
  
 (a) Upon execution and delivery of this Agreement, it will be the valid and binding obligation of the Inventor, enforceable in accordance
with its terms, subject to equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting creditor’s rights and remedies generally. 
  
 (b) The execution, delivery and performance of this
Agreement does not, and the consummation of the transactions contemplated herein will not, violate any order, judgment or decree binding on the Inventor, or result in a breach of any contract, agreement or other instrument to which the Inventor is a
party or, to the best of the Inventor’s knowledge, violate any law, rule or regulation applicable to the Inventor, except in each case to an extent not material. 
  

 10 

 (c) The Inventors are the sole owners of the entire right, title and interest in and to
the Endoscopic Invention and no other person or entity has any license, claim or other right or interest in or to the Endoscopic Invention. 
  
 (d) To the best of the Inventor’s knowledge, neither the Endoscopic Invention nor the CMU Technology infringes, misappropriates or
otherwise conflicts with any intellectual property or other rights of any third party and the Inventor has not received notice from any third party of any such claim. 
  
 (e) The Inventor is not aware of any infringement or misappropriation of the Endoscopic Invention or CMU
Technology by any third party. 
  
 (f) There are
no judicial, arbitral, regulatory or administrative proceedings or investigations, claims, actions or suits relating to the Endoscopic Invention or CMU Technology pending against or, to the best of the Inventor’s knowledge, threatened against
the Inventor or his or her Affiliates in any court or by or before any governmental body or agency and, to the best of Inventor’s knowledge, no such judicial, arbitral, regulatory or administrative proceedings or investigations, actions or
suits have been threatened against the Inventor or his or her Affiliates. 
  
 Section 7.4 LIMITATION ON WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NO PARTY MAKES ANY REPRESENTATION OR WARRANTY TO ANY OTHER PARTY, WHETHER EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION
OF LAW, BY STATUTE OR OTHERWISE, AND THE PARTIES SPECIFICALLY DISCLAIM ANY AND ALL IMPLIED OR STATUTORY WARRANTIES, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE. 
  
 ARTICLE 8 
 INDEMNIFICATION; INSURANCE 
  
 Section 8.1 Indemnification. 
  
 (a) Spectral Indemnification. Spectral shall indemnify and hold forever harmless each Inventor, CDI and their Affiliates, agents, directors, officers and employees from and against any loss, damage, action,
proceeding, expense or liability (including reasonable attorneys’ fees) arising from or in connection with: (i) the breach or inaccuracy of any representation or warranty made by Spectral in this Agreement; (ii) the gross negligence
or willful misconduct of Spectral or its Affiliates or any of their agents, directors, officers or employees; (iii) the development, manufacture, use, commercialization (including, without limitation, promotion, distribution, advertising,
offering for sale, sale or other disposition, transfer, importation or exportation), labeling, handling or storage of any Product; and (iv) any infringement claim or action and/or any misappropriation claim or action, whether threatened or
asserted, that relates to the Endoscopic Invention or the CMU Technology, but only to the extent that both (A) Spectral, its Affiliates, licensees or sublicensees modify the Endoscopic Invention or CMU Technology following the execution of this
Agreement and (B) the unmodified Endoscopic Invention or CMU Technology would not be subject to the same claims. 
  

 11 

 (b) CDI Indemnification. CDI shall indemnify and hold forever harmless Spectral,
its Affiliates and each of their agents, directors, officers and employees from and against any loss, damage, action, proceeding, expense or liability (including reasonable attorneys’ fees) arising from or in connection with: (i) the
breach or inaccuracy of any representation or warranty made by CDI in this Agreement; (ii) the gross negligence or willful misconduct of CDI or its Affiliates or any of their agents, directors, officers or employees; and (iii) except for
claims and actions for which Spectral has an indemnification obligation pursuant to Section 8.1(a), any infringement claim or action and/or any misappropriation claim or action, whether threatened or asserted, that relates to the Endoscopic
Invention or CMU Technology. 
  
 (c) Inventor
Indemnification. Each Inventor shall jointly and severally indemnify and hold forever harmless Spectral, its Affiliates and each of their agents, directors, officers and employees from and against any loss, damage, action, proceeding, expense or
liability (including reasonable attorneys’ fees) arising from or in connection with: (i) the breach or inaccuracy of any representation or warranty made by the Inventor in this Agreement; (ii) the gross negligence or willful
misconduct of the Inventor; and (iii) except for claims and actions for which Spectral has an indemnification obligation pursuant to Section 8.1(a), any infringement claim or action and/or any misappropriation claim or action, whether
threatened or asserted, that relates to the Endoscopic Invention or CMU Technology. 
  
 Section 8.2 Procedure. The indemnities set forth in this Article 8 are subject to the condition that the party seeking indemnification shall forthwith notify the indemnifying party on being notified or
otherwise made aware of a suit, action or claim and that the indemnifying party defend and control any proceedings, with the indemnified party being permitted to participate at the indemnified party’s expense (unless a conflict of interest
prevents representation by joint counsel, in which event the indemnifying party shall pay for the indemnified party’s counsel); provided that the indemnifying party may not settle the suit or otherwise consent to any judgment in such suit
without the written consent of the indemnified party (such consent not to be unreasonably withheld). 
  
 Section 8.3 DISCLAIMER. NO PARTY WILL BE LIABLE TO THE ANY OTHER PARTY FOR ANY CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES OR EXPENSES, INCLUDING
DAMAGES FOR LOST PROFITS, LOSS OF OPPORTUNITY OR USE OF ANY KIND, SUFFERED BY THE OTHER PARTY, WHETHER IN CONTRACT, TORT OR OTHERWISE. 
  
 Section 8.4 Insurance. During the Term and for a period of two (2) years thereafter, Spectral shall obtain, or cause its licensee or
sublicensee to obtain at its sole cost and expense, liability insurance applicable to its performance under this Agreement, that meets the following requirements: 
  
 (a) the insurance shall insure Spectral and any such licensee or sublicense against all liability related to
their activities relating to the development, manufacture and sale of Products, including liability for bodily injury, property damage or wrongful death; and 
  

(b) the insurance must be in amounts that are reasonable and customary in the in the medical device industry in the United States. Each
such policy must include a contractual 

  

 12 

 
endorsement naming each Inventor as an additional insured and require the insurance carrier to provide each Inventor with no less than thirty
(30) days’ written notice of any change in the terms or coverage of the policy or its cancellation. 
  
 ARTICLE 9 
 TERM; TERMINATION 
  
 Section 9.1 Term. This Agreement will commence on the date hereof and
will continue until the later of 15 years from the date of this Agreement or the last to expire of any of the Patent Rights (the “Term”), unless earlier terminated in accordance with the provisions of Section 9.2. 
  
 Section 9.2 Termination of Agreement. This Agreement may be terminated
prior to the expiration of the Term: 
  
 (a) By
mutual written consent of CDI, the Inventors and Spectral. 
  
 (b) By the Inventors upon thirty (30) days prior written notice to Spectral, if Spectral (i) fails to raise four hundred thousand dollars ($400,000) or more, in the aggregate from one or more debt or equity
financings, financings in kind, and grants from governmental or other agencies within eighteen (18) months of the date of this Agreement and has not otherwise been able to undertake development efforts for the CMU Technology or the Endoscopic
Invention, or (ii) fails to invest or make binding commitments to invest, within eighteen (18) months of the date of this Agreement, one hundred sixty thousand dollars ($160,000) or more in the development and commercialization of Products
under this Agreement, as evidenced by proof reasonably acceptable to each Inventor. 
  
 (c) Upon written notice by a party if (i) another party is dissolved or liquidates, unless such dissolution or liquidation results
from a reorganization, acquisition, merger or similar event, or (ii) bankruptcy or insolvency proceedings, including any proceeding under Title 11 of the U.S. Code, have been brought by or against another party and, in the event such a
proceeding has been brought against such party, remains undismissed for a period of sixty (60) days, or an assignment has been made for the benefit of such party’s creditors or a receiver of such party’s assets has been appointed.

  
 (d) By the Inventors or CDI, upon sixty
(60) days prior written notice, if Spectral is in Default, and fails to cure such breach within sixty (60) days following receipt of written notice from the non-breaching party specifying the breach to be cured. 
  
 (e) By Spectral, upon sixty (60) days prior written
notice, if CDI or the Inventors are in Default, and fail to cure such breach within sixty (60) days following receipt of written notice from the non-breaching party specifying the breach to be cured. 
  
 Section 9.3 Rights Upon Expiration of the Term or Earlier Termination.
Upon expiration of the Term or earlier termination pursuant to Section 9.2, the licenses granted in Article 2 will terminate. 
  

 13 

 Section 9.4 Surviving Rights. Termination of this Agreement for any reason will not effect:

  
 (a) The rights and obligations of the parties
provided in Section 4.5, Article 6, and Article 8, all of which will survive termination; 
  
 (b) Any other rights, obligations or liabilities which shall have accrued to the benefit of a party prior to such termination (including
without limitation Spectral’s obligation to pay all royalty payments which have accrued hereunder as of the effective date of such termination); and 
  
 (c) Any other rights of remedies provided at law or in equity which a party may otherwise have against the another party. 
  
 ARTICLE 10 
 MISCELLANEOUS 
  
 Section 10.1 Notices. 
  
 (a) Every notice or other communication required or contemplated by this Agreement must be in writing and sent by one of the following methods: 
  
 (i) personal delivery, in which case delivery will be deemed to occur the day of delivery; 
  
 (ii) certified or registered mail, postage prepaid, return
receipt requested, in which case delivery will be deemed to occur the day it is officially recorded by the U.S. Postal Service as delivered to the intended recipient; or 
  
 (iii) next-day delivery to a U.S. address by recognized overnight delivery service such as FedEx, in which
case delivery will be deemed to occur upon receipt. 
  
 (b) In each case, a notice or other communication sent to a party must be directed to the address for that party set forth below, or to another address designated by that party by written notice: 
  
 If to CDI, to: 
  
 ChromoDynamics, Inc. 
 1195 Airport Road, Unit #1 
 Lakewood, New
Jersey 08701 
 Attention:
                                 
  
 If to Spectral, to: 
  
 Spectral Molecular Technologies, Inc. 
  
 ______________________________ 
 Attention: Sanford J. Hillsberg 
  

 14 

 If to Daniel L. Farkas, to: 
  
 Daniel L. Farkas 
  
 ______________________________ 
  
 If to Miriam Farkas, to: 
  
 Miriam Farkas 
  
 ______________________________ 
  
 If to Elliott Wachman, to: 
  
 Elliott Wachman 
  
 ______________________________ 
  
 If to Jill Wachman, to: 
  
 Jill Wachman 
  
 ______________________________ 
  
 Section 10.2 Governing Law. This Agreement is governed by the laws of the State of California without giving effect to principles of conflict of
laws. 
  
 Section 10.3 Jurisdiction; Service of Process. A
party may initiate in the courts of the State of California, County of Los Angeles, or, if it has or can acquire jurisdiction, in the United States District Court for the Central District of California, any proceeding seeking to enforce any
provision of this Agreement. Each of the parties consents to the jurisdiction of those courts (and of the appropriate appellate courts) in any such action or proceeding and waives any objection to venue laid therein. Process in any such action or
proceeding may be served by delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of notices in Section 10.1. Nothing in this Section 10.3, however, affects the right of any
party to serve legal process in any other manner permitted by law. 
  
 Section 10.4 Non-waiver of Rights. Except as specifically provided for herein, the waiver from time to time by a party of any of its rights or a party’s failure to exercise any remedy will not operate or be construed as a
continuing waiver of the same or of any other rights or remedies provided in this Agreement. 
  
 Section 10.5 No Agency. No party will, by virtue of this Agreement, have any power to bind any other party to any obligation nor will this Agreement create any relationship of agency, partnership or joint
venture. 
  
 Section 10.6 Severability. If any provision of
this Agreement is held unenforceable by any court of competent jurisdiction, all other provisions of this Agreement will remain effective. If any provision of this Agreement is held to be unenforceable only in part or degree, it will remain
effective to the extent not held unenforceable. 
  

 15 

 Section 10.7 Entire Agreement. This Agreement constitutes the entire agreement of the parties
pertaining to the subject matter of this Agreement. It supersedes all prior agreements of the parties, whether oral or written, pertaining to the subject matter of this Agreement. 
  
 Section 10.8 Amendment. This Agreement may not be amended except by an instrument in writing signed on behalf of all
parties to this Agreement. 
  
 Section 10.9 Assignment. No
party may, without the prior written consent (not to be unreasonably withheld or delayed) of the other parties having been obtained, assign or transfer this Agreement to any Third Party, provided, however, that Spectral may assign this
agreement in connection with a sale of all or substantially all of its assets or a merger or other similar transaction, and each party may assign or transfer this Agreement to any Affiliate of such party without the prior written consent of any
other party hereto, provided that the assigning party guarantees the performance of its Affiliate. 
  
 Section 10.10 Counterparts. This Agreement may be executed in counterparts, each of which is an original and all of which together constitute one
and the same instrument. 
  
 Section 10.11 License Survival
During Bankruptcy. All rights and licenses granted under or pursuant to this Agreement to the CMU Technology, if applicable, are, and will otherwise be deemed to be, for purposes of Paragraph 365(n) of the U.S. Bankruptcy Code, licenses of
rights to “Intellectual Property” as defined under Paragraph 101(35A) of the U.S. Bankruptcy Code. The parties agree that Spectral, as a licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and
elections under the U.S. Bankruptcy Code, subject to performance by Spectral of its obligations under this Agreement. 
  
 [Remainder of page left blank intentionally.] 
  

 16 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized
representatives as of the day and year first indicated above. 
  

					
	 CHROMODYNAMICS, INC.

		
	By: 	 	 /s/ Jill Wachman

	 	 	 Name: 
	 	 Jill Wachman, M.D.

	 	 	 Title: 
	 	 Vice President

	
	 SPECTRAL MOLECULAR
 TECHNOLOGIES, INC.

		
	By: 	 	 /s/ Manfred Mosk

	 	 	 Name: 
	 	 Dr. Manfred Mosk

	 	 	 Title: 
	 	 Interim Chief Executive Officer

  

	
	
	 /s/ Daniel L. Farkas

	 DANIEL L. FARKAS

	
	 /s/ Miriam Farkas

	 MIRIAM FARKAS

	
	 /s/ Elliot Wachman

	 ELLIOTT WACHMAN

	
	 /s/ Jill Wachman

	 JILL WACHMAN

  

 17 

 EXHIBIT A 
  

CMU TECHNOLOGY 
  
 (SEE ALSO COPY CMU LICENSE AGREEMENT ATTACHED HERETO) 
  

	1.	All technologies covered under the following U.S. Patents: 

  

	 	•	 	U.S. Patent 5,796,512: Sub-Micron Imaging System Having an Acousto-optic Tunable Filter 

  

	 	•	 	U.S. Patent 5,841,577: Light Microscope Having Acousto-optic Tunable Filter 

  

	2.	All software that has been developed by Drs. Wachman and Farkas and Mr. Wen-hua Niu, prior to the Effective Date of the CMU License Agreement, and related to the
technologies which are referenced in #1 above: 

  

	 	a)	software required to run microscope system (I/O, electronics and hardware control, etc. 

  

	 	b)	AOTF-derived image processing routines 

  

	 	c)	AOTF crystal design and modeling routines 

  

	 	d)	spectral analysis software 

  

	 	e)	3-D spectral visualization routines 

  
 Applications include but are not limited to: 
  

	3.	In-vitro spectral imaging (fixed specimens, ex-vivo, or live cells) 

  

	 	a)	brightfield 

  

	 	b)	reflected light 

  

	 	c)	fluorescence 

  

	 	d)	pathology/histology 

  

	 	e)	FISH 

  

	4.	In-vivo spectral imaging 

  

	 	a)	endoscopy by AOTFs 

  

	 	b)	surface imaging by AOTFs (dermascopy) 

  

	 	c)	non-invasive sub-surface imaging by AOTFs (oxygen sensing, etc.) 

  

	 	d)	Optical Coherence Tomography using AOTFs 

  

	5.	Macroscopic spectral imaging 

  

	6.	Use of AOTF system for illumination in combination with a different spectral system for detection (Liquid Crystal Tunable filter system, Sagnac interferometer-based system, etc.)

  

 18 

 EXHIBIT B 
  

ENDOSCOPIC INVENTION 
  
 IMAGING ELASTIC SCATTERING SPECTROSCOPY 
  
 Inventors; Daniel L. Farkas, PhD; Elliot S. Wachman, PhD; Jill Wachman, MD; Miriam Farkas, MD 
  
 BACKGROUND OF THE INVENTION 
  
 Field of the Invention 
  
 [0001] The present invention is broadly concerned with providing a non-invasive technique for the early detection of cancer and other
abnormal tissue and, more particularly, to the field of imaging elastic scattering spectroscopy (IESS). 
  
 Description of the Background 
  
 [0002]
Detecting abnormal tissue early is critical to the successful treatment of disease. Life expectancy of patients with malignancy or cancer, for example, can increase dramatically when abnormal tissue is identified while still in a pre-malignant
state. Such tissue regions, dysplasia and carcinoma in situ being typical examples, are ordinarily detected by surgical biopsy. The removed tissue is sent to a pathologist, where it is examined under a microscope for the characteristic morphological
changes that indicate abnormal cell growth. Upon receiving the pathology report, the physician can then decide whether further removal of the tissue is indicated. 
  
 [0003] This method of treatment has a number of serious drawbacks. For example, only a limited number of regions can be biopsied,
with the choice of region determined only by its gross appearance in the eyes of the physician. It is therefore quite likely that a problem area, particularly one in an early stage of abnormality, may be missed completely. Another serious drawback
of this method of treatment is that since the identification of abnormality must await the pathology report, surgical removal of the abnormal tissue often must be performed during a separate procedure (and sometimes even by successive iterations),
thereby increasing risk to the patient, and inconvenience and cost for both the patient and the physician. 
  
 [0004] Within the last decade or so, a number of all-optical techniques for identifying abnormal tissue have been developed in an attempt to avoid these problems. These approaches have the potential for
allowing problem sites to be detected over a large area sensitively and quickly, without having to rely on the subjective judgment of the physician. In addition, because suspicious areas can be identified during the initial examination, diseased
tissue can be removed immediately, and completeness of the excision assessed by prompt reimaging of the area in question. 
  
 [0005] The most developed of these optical techniques makes use of differences in the spectra of fluorescence exhibited by normal and abnormal tissue. This
fluorescence is ordinarily excited by laser illumination, and can be either intrinsic or extrinsic. Although numerous groups are working on the development of fluorescence-based systems for cancer diagnosis, to date only one device has reached the
commercial market. The LIFE scope, manufactured by Xillix Inc. and marketed by Olympus, Inc., uses ultraviolet laser light to excite tissue autofluorescence through a bronchoscope. It is presently being used by approximately 50 groups worldwide with
a cost of upwards of $200,000 per unit. Although this device provides much greater sensitivity than standard white-light bronchoscopy, single procedures can be very time consuming. Even experienced surgeons often require 45 minutes to perform one
examination which would take only 3 minutes using standard bronchoscopy equipment. The use of the LIFE scope is not only quite draining for the patient and physician, but also limits greatly the number of patients that can be seen, thereby
substantially increasing procedure cost. 
  
 [0006] Other groups have used
Raman signals to identify abnormal tissue, however these signals are extremely weak, and it may be difficult to implement as a practical clinical tool. 
  
 [0007] A third approach, elastic scattering spectroscopy (ESS), illuminates the sample, and looks at the spectral content of the light scattered from tissue right
beneath the surface by using a point probe in contact with the tissue surface. This method has the capability of detecting disorganized epithelial orientation and architecture, morphological changes in epithelial surface texture and thickness, cell
crowding, enlargement and hyperchromicity of cell nuclei, increased concentration of metabolic organelles, and the presence of abnormal protein packages. ESS has been used to study the skin, the eyes, the bladder, the prostate and many different
regions of the gastrointestinal tract. In one study, ESS was used to differentiate neoplastic from non-neoplastic tissue and adenomatous polyps from hyperplasic polyps in the colon with a predictive accuracy of ~85%. In another study ESS was used to
detect 

  

 19 

 
bladder cancer with a sensitivity of 100% and a specificity of 97%. Preliminary tests of this technique in the lower GI tract demonstrated the ability of
differentiating between dysplasia, adenoma/adenocarcinoma, and normal mucosa with a sensitivity of 100% and a specificity of 98%. Studies in the skin have demonstrated a sensitivity of 90.3% and a specificity of 77.4% for distinguishing primary
melanomas from benign nevi. Over a decade of clinical trials with this instrument in a variety of organ systems has shown that these spectra can provide a sensitivity means of detecting even early abnormal tissue. At present, however, this method is
capable of providing single point measurements only, thereby making it inappropriate for routine clinical use. 
  
 [0008] Therefore, there is a need in the art for a system for detecting ESS signals in a full imaging mode which can be equally applicable to imaging endoscopically and imaging externally for routine clinical
use. 
  
 SUMMARY OF THE PRESENT INVENTION 
  
 [0009] One aspect of the present invention is a method of generating data which
comprises illuminating a target with polarized light and serially imaging the target at both parallel and perpendicular polarizations for each of a plurality of different wavelengths. The serially imaging may include: illuminating the target with a
wavelength-tunable light source; illuminating the target with a broadband light source in series with a wavelength-tunable filter; illuminating the target with a broadband light source and detecting reflected light with a detector whose wavelength
acceptance can be chosen by interposing chromatic filters in the light path; or illuminating the target with a broadband light source and detecting reflected light with a wavelength-tunable filter in series with a detector. 
  
 [0010] Another aspect of the present invention is a method of generating data which
comprises illuminating a target with polarized light, serially imaging the target at both parallel and perpendicular polarizations for each of a plurality of different wavelengths and determining range information indicative of a distance to the
target. Again, the serially imaging may include: illuminating the target with a wavelength-tunable light source; illuminating the target with a broadband light source in series with a wavelength-tunable filter; illuminating the target with a
broadband light source and detecting reflected light with a detector whose wavelength acceptance can be chosen by interposing chromatic filters in the light path or illuminating the target with a broadband light source and detecting reflected light
with a wavelength-tunable filter in series with a detector. Additionally, determining range information may be accomplished optically, sonically and/or mechanically. Further, determining range information may be accomplished by illuminating a spot
of the target with a collimated beam of known diameter and degree of collimation, recording the size of the illuminated spot reflected from the target, and calculating the distance to the target using the size of the illuminated spot and the known
diameter and degree of collimation of the beam. 
  
 [0011] Another aspect
of the present invention is screening for abnormal cells and is comprised of illuminating a target with polarized light, serially producing a series of images of the target at both parallel and perpendicular polarizations for each of a plurality of
different wavelengths, determining a distance to the target, and analyzing the series of images based on the distance to identify abnormal cells. The analysis may include an analysis based on Mie theory mathematics. 
  
 [0012] The present invention is also directed to an apparatus comprising a light
source for generating polarized light. Means are provided to convey the polarized light to a target. A collector receives light reflected from the target. A detector is responsive to the collector for generating images at both parallel and
perpendicular polarizations for each of a plurality of wavelengths. A range finder detects a distance to the target. The apparatus is under the control of control electronics and may be configured to image areas on the surface of the body, or
configured so as to be inserted into various body cavities. Typically, the apparatus would be used in conjunction with an analyzer for analyzing the images for evidence of abnormal cells. 
  
 [0013] To enable the generation of images at a plurality of wavelengths, either the source of light or the detector is wavelength
tunable. The polarizers may include any of a variety of known polarizing devices including, but not limited to a polarizing sheet, a polarizing beamsplitter, or a polarizing-preserving fiber. The range finder may be an optical, acoustical and/or
mechanical device. 
  
 [0014] The present invention provides a non-invasive
technique for the early detection of cancer and other abnormal tissue. The present invention allows for detecting ESS signals in a full imaging mode which can be equally applicable to imaging endoscopically and imaging externally for routine
clinical use. 
  

 20 

 BRIEF DESCRIPTION OF THE DRAWINGS 
  
 [0015] To enable the present invention to be easily understood and readily practiced, the present invention will now be described for
purposes of illustration and not limitation, in connection with the following figures wherein: 
  
 [0016] FIG. 1 illustrates an apparatus constructed according to the present invention used in a process for screening for abnormal cells; 
  
 [0017] FIG. 2 is a block diagram of one embodiment of the apparatus shown in FIG. 1; 
  
 [0018] FIG. 3 is a diagram illustrating the steps of a method of screening according
to the present invention; 
  
 [0019] FIG. 4 is a diagram of another
embodiment of the present invention useful for screening for abnormal cells in a body cavity; 
  
 [0020] FIG. 5A is a detailed diagram illustrating a port element which may be a component of the present invention; 
  
 [0021] FIGS. 5B and 5C are detailed diagrams illustrating a range finding mechanism useful for determining the distance between the tissue and probe which may be a
component of the present invention; and 
  
 [0022] FIGS. 6A and 6B are
detailed diagrams illustrating alternative embodiments for the collection components of the present invention. 
  
 DETAILED DESCRIPTION OF THE INVENTION 
  
 [0023] One embodiment of an apparatus 10 constructed according to the teachings of the present invention and useful for screening for abnormal cells is illustrated in FIG. 1. In FIG. 1, a patient 12 is
positioned on an examining table 14. A target 16 is examined by apparatus 10 as will be described in detail below. Those of ordinary skill in the art will recognize that target 16 is meant to be exemplary and not limiting. 
  
 [0024] Most internal and external surfaces of the body are covered with a layer of
cells known as the epithelium. One of the more common types of epithelial tissue is known as the “columnar epithelium”, in which a single layer of epithelial cells lies on top of the thicker sub-mucosal layer. In such a case, the
epithelial nuclei can be considered as scattering spheres embedded in a surrounding uniform medium of different optical composition. 
  
 [0025] The way that light scatters in such a situation depends upon a number of factors: scattering angle, sphere size, wavelength and polarization of the light
being scattered, as well as the optical properties of the spheres and surrounding medium. The mathematics used to describe this scattering is known as the Mie theory. Hence, if the wavelengths and polarization of the illumination light, the
detection angle, and the optical properties of the tissue are know, the Mie theory can be used to calculate the size of the nuclear spheres responsible for the observed scatter. If a camera is used to produce images of the light reflected from the
target 16, then an analysis of the images will result in a map of nuclear size at each point in the tissue imaged. This is the basis of imaging elastic scattering spectroscopy (IESS). 
  
 [0026] The apparatus 10 shown if FIG. 1 is illustrated in greater detail in FIG. 2. In FIG. 2, a light source 20 is used to generate
polarized light. The light source 20 may be comprised of a filament 22 or other source of light. Filament 22 may be a tunable light source or a broadband light source. Should filament 22 be a tunable light source, it is preferably capable of rapidly
switching between wavelengths. Should filament 22 be a broadband light source, a tunable filter 24 may optionally be used in series with filament 22 to provide light at discrete wavelengths. Tunable filter 24 should be a device that is capable of
rapidly switching between wavelengths, such as an acousto-optic tunable filter (AOTF) or monochromator. The light 29 from light source 20 exists device 10 through an illumination port 30 for illuminating the target 16. The light source 20 is
directly in line with illumination port 30, or fiber optics may be used to convey light to the illumination port 30. Additionally, a polarizer 26 may be included in light source 20 within the light path to polarize the light. Polarizer 26 could be
any device that polarizes light, for example, a polarizing sheet, a polarizing beamsplitter, a polarizing-preserving fiber, among others. Those of ordinary skill in the art will recognize that polarizer 26 may be any polarizing element known in the
art. The light source is under the control of control electronics 28. 
  
 [0027] Target 16 may be any tissue, including external tissue, such as the skin, or internal tissue such as those accessible endoscopically or otherwise, as will be described below. The light 29 is polarized at this point and may be
serially tuned through a plurality of wavelengths by the filter 24. Alternatively, and as will become apparent, the light could remain broadband, with the tuning occurring on the detection side of apparatus 10. 
  
 [0028] Light 32 reflected from target 16 is received by an imaging port 34. A
collector, or series of collection components, 36 is responsive to the light 32 collected at the imaging port 34. Collection components 36 may include polarization filters 38 and imaging optics 40. An imaging detector 42 is responsive to the
collector 36 for generating images at both parallel and perpendicular polarizations for each of a plurality of wavelengths. If filament 22 is a broadband light source, and light source 20 does not include tunable filter 24, collection components 36
may contain a tunable filter 24 to provide for spectral discrimination. Tunable filter 24 should be a device that is capable of rapidly switching between wavelengths, such as an acousto-optic tunable filter (AOTF) or monochromator The 

  

 21 

 
imaging detector 42 is under the control of control electronics 28 and, when collector 36 contains a tunable filter, the collector 36 will also be under the
control of control electronics 28. 
  
 [0029] Apparatus 10 includes a range
finder 44 for detecting the distance between a range finding port 45 and target 16. Ranger finder 44 may be implemented using any known form of optical, acoustical (sonic) or mechanical range finding device. Range finder 44 is under the control of
control electronics 28 and will produce range information for each target 16. 
  
 [0030] An analyzer 46, which may be integral with apparatus 10 or remote from apparatus 10, is responsive to the images and the range information. Based on the range information, the images are analyzed to identify abnormal cells
using the aforementioned Mie theory. 
  
 [0031] A method of operating the
apparatus 10 of the present invention is illustrated in FIG. 3. In FIG. 3, at step 50, polarized light 29 is used to illuminate target 16. At step 52, light reflected from the target is collected. At step 54 the collected light is used to serially
create images at both parallel and perpendicular polarizations at a plurality of wavelengths. The resulting set of images provides elastic scattering spectra at each imaged point. 
  
 [0032] Step 50 may include illuminating the target with a tunable light source or a broadband light source in series with a tunable
filter. Alternatively, step 50 may include illuminating the target with a broadband light source and step 54 may include detecting reflected light with a tunable detector or with a tunable filter in series with a detector. 
  
 [0033] At step 56 range information indicative of the distance to the target, e.g. the
distance between the target and the range finding port 45, is generated. The range information may be generated optically, sonically, or mechanically. Although FIG. 3 illustrates the range finding step after steps 50, 52 and 54, the range finding
operation can be performed either before or in parallel with steps 50, 52 and/or 54. 
  
 [0034] Steps 50, 52 and 54 may be referred to as a method of generating data as those steps result in the production of the images needed to screen for abnormal cells. The method of generating data may also include the range finding
operation represented by step 56. 
  
 [0035] At step 58 the generated
images are analyzed based on the distance information. This analysis may include an analysis based on the Mie theory. The analysis may determine the nuclear size distribution point-by-point throughout the imaged region. Because size information is a
parameter often used by a pathologist when diagnosing biopsied tissue, the analysis results may optionally be pictorially displayed before the physician (with, for example, different sizes depicted in false color), thereby providing a near real-time
assessment of the nature of the tissue being examined. Those of ordinary skill in the art will recognize that the screening for abnormal cells can be done offline. That is, steps 50, 52, 54 and 56 may be performed and the data transmitted to a
remote location for analysis or stored for later analysis. 
  
 [0036] FIG.
4 illustrates another embodiment of the present invention in which the apparatus 10’ is configured for screening for abnormal cells in a body cavity. A portion of the apparatus 10’ may be designed as an imaging probe to be inserted into
and removed from an instrument channel of a conventional endoscope 64, or incorporated as a permanent additional port in a modified endoscope. 
  
 [0037] As shown FIG. 4, light source 20 may be a spectral light source. Light source 20 may be a monochromator (Polychrome IV, Till Photonics, Eugene, OR) or
AOTF-based source (ChromoDynamics, Inc., Lakewood, NJ), fed through a first optical fiber 66 which leads to the distal end of an endoscope probe. First optical fiber 66 provides a means for conveying the polarized light. In an endoscopic embodiment,
fiber optics are the most practical way of conveying the light from the light source. In other embodiments, mirrors, beam splitters, prisms, reflective devices, fiber optics, direct paths and the like may be used as means for conveying. Polarization
of the illumination light may be provided by sheet polarizers (not shown) at the two illumination ports 30 (see FIG. 5A) instead of using polarizer 26 as shown in FIG. 2, or by other means. The single imaging port 34 (see FIG. 5A) has a second
optical path (which may be provided by a pair of optical fibers or a lens system as shown in FIGs. 6A and 6B) responsive thereto to direct the collected light to the collector 36 discussed in detail with FIGS. 6A and 6B. The optical fiber 66 has an
outer diameter and length compatible with insertion down the instrument channel of conventional endoscopes (for many scopes, this necessitates an outer diameter less than 2.0 mm). 
  
 [0038] FIG. 5A illustrates range finding port 45. FIGS. 5B and 5C illustrate a simple, inexpensive range finding mechanism useful for
determining the distance between the tissue and probe. Range finding may be implemented using a low-power, infrared laser diode fed fiber-optically into an optical range-finding port at the distal end of the endoscope. The output optic on this port
will collimate this beam as much as possible to insure that the exiting beam has a very low divergence angle. For a given starting beam diameter and degree of collimation, the size of the spot illuminated on the tissue as a proportion of the entire
illuminated field-of-view will vary depending upon the tissue-probe separation, as shown schematically in FIGS. 5B and 5C. At larger separations (as shown in FIG. 5B) the near-collimated range finding laser spot takes up a smaller area of
illuminated field of view than at smaller separations (as shown in FIG. 5C). The laser can then be pulsed on once, or several times, per image set, the size of the reflected spot in the tissue measure, and from this, the tissue-probe distance
calculated. Although this technique 

  

 22 

 
will provide a reasonable determination of distance only in the center of the images field, this should be sufficient for the purposes of the IESS analysis,
particularly in regions of fairly regular topology (such as, for example, the esophagus) where tissue-probe distances throughout the imaged area can be readily extrapolated from the value measured at the center of the field. In addition, topology of
the illuminated region may also be adduced by looking at the size and shape of the illuminated region. 
  
 [0039] A camera 68 is affixed to the proximal end of the endoscope 64. The images may be captured with a high-speed black-and-white charged coupled device (CCD) camera (SensiCam VGA, Cooke Corporation, Auburn
Hills, MI) and sent to a PC computer 70 that performs the function of the analyzer in FIG. 2. PC 70 may contain software and/or hardware for image analysis, classification and display. Camera 68 may be an independent unit proximately mounted to
apparatus 64, or an integrated part of apparatus 64, such as an embedded camera chip. Camera 68 is preferably capable of high-speed operation and broad sensitive spectral response for image acquisition. 
  
 [0040] FIGS. 6A and 6B show examples of other configurations of collection components
36 which may be used. As shown in FIG. 6A and 6B either polarizing sheets 76 or polarization beam splitting optics 84 can be used to split the parallel and perpendicular polarizations. Collector 36 can include imaging optics 40. Collector 36 may
include a portion of optical fibers 79 and 80 or a lens assembly which provide a second optic path 78. The collector 36 may also include collection optics as shown in FIG. 6B. Collector 36 may include a tunable filter 24 such as an AOTF-tunable
imaging filter (ChromoDynamics, Inc.). 
  
 [0041] The fiber optic path
provided by the collector 36 may provide a coherent imaging bundle or bundles of optical fibers to deliver images to external camera 68, or to focus the images onto a camera chip (not shown) within endoscope 64. This may also be done by an
appropriately designed lens assembly instead of optical fibers. If collection components 36 includes a tunable filter 24 (not shown), tunable filter 24 may be located at any suitable location in the light path. 
  
 [0042] FIGs. 6A and 6B are intended to illustrate that numerous alternative
embodiments of the present invention may be devised by those of ordinary skill in the art. The exact sequence of tuning, polarizing and focusing the light, and whether the tuning is performed on the input side (i.e. prior to the target) or the
output side (i.e. after the target) is of no consequence to the present invention. Many components other than those disclosed may be used to perform the desired function, and the selection of one type of component over another may dictate other
components that need to be in the light path. Thus, while the present invention has been described in conjunction with presently preferred embodiments, those of ordinary skill in the art will recognize that many modifications and variations are
possible. The present invention is intended to be limited only by the scope of the following claims and not by the scope of the disclosed exemplary embodiments. 
  

 23 

 What is claimed is: 
  
 1. A method of generating data, comprising: 
  
 illuminating a target with polarized light; and 
  
 serially imaging said target at both parallel and perpendicular polarizations for each of a plurality of different wavelengths. 
  
 2. The method of claim 1 wherein said serially imaging includes illuminating the target with
a wavelength-tunable light source. 
  
 3. The method of claim 1 wherein said
serially imaging includes illuminating the target with a broadband light source in series with a wavelength-tunable filter. 
  
 4. The method of claim 1 wherein said serially imaging includes illuminating the target with a broadband light source and detecting reflected light with a detector whose
wavelength acceptance can be chosen by interposing chromatic filters in the light path. 
  
 5. The method of claim 1 wherein said serially imaging includes illuminating the target with a broadband light source and detecting reflected light with a wavelength-tunable filter in series with a detector. 
  
 5a. The method of claim 1 wherein said wavelength tunable filter is an AOTF. 
  
 6. A method of generating data, comprising: 
  
 illuminating a target with polarized light; 
  
 serially imaging said target at both parallel and perpendicular polarizations
for each of a plurality of different wavelengths; and 
  
 determining range information indicative of a distance to the target. 
  
 7. The method of claim 6, wherein said serially imaging includes illuminating the target with a wavelength-tunable light source. 
  
 8. The method of claim 6 wherein said serially imaging includes illuminating the target with a broadband light source in series with a wavelength-tunable filter.

  
 9. The method of claim 6 wherein said serially imaging includes illuminating
the target with a broadband light source and detecting reflected light with a detector whose wavelength acceptance can be chosen by interposing chromatic filters in the light path. 
  
 10. The method of claim 6 wherein said serially imaging includes illuminating the target with a broadband light source and detecting
reflected light with a wavelength-tunable filter in series with a detector. 
  
 10a. The method of claim 6 wherein said wavelength tunable filter is an AOTF. 
  
 11. The method of claim 6 wherein said determining includes either optically, sonically or mechanically determining range information. 
  
 12. The method of claim 6 wherein said determining range information comprises: 
  

illuminating a spot of said target with a collimated beam of known diameter and degree of collimation; 
  
 recording the size of the illuminated spot reflected from said target; and

  
 calculating the distance to said target using the size of the
illuminated spot and the known diameter and degree of collimation of the beam. 
  
 13. A method of screening for abnormal cells, comprising: 
  
 illuminating a target with polarized light; 
  
 serially
producing a series of images of said target at both parallel and perpendicular polarizations for each of a plurality of different wavelengths; 
  

 24 

 determining a distance to the target; and 
  
 analyzing said series of images based on said distance. 
  
 14. The method of claim 13, wherein said analyzing includes an analysis based on a Mie theory. 
  
 15. A method of screening for abnormal cells, comprising: 
  
 generating polarized light; 
  
 directing said polarized light onto a target; 
  
 collecting polarized light reflected from the target; 
  
 serially generating images at both parallel and perpendicular polarizations
for each of a plurality of different wavelengths from said gathered polarized light; 
  
 determining a distance to the target; and 
  
 analyzing said generated images based on the distance to determine cell structure. 
  
 16. The method of claim 15, wherein said analyzing includes an analysis based on a Mie theory. 
  
 17. The method of claim 15 wherein said determining includes either optically, sonically, or mechanically determining the distance to the
target. 
  
 18. The method of claim 15 wherein said determining comprises:

  
 illuminating a spot of said target with a collimated beam of
known diameter and degree of collimation; 
  
 recording the size
of the illuminated spot reflected from said target; and 
  
 calculating the distance to said target using the size of the illuminated spot and the known diameter and degree of collimation of the beam. 
  
 19. An apparatus, comprising: 
  
 a light source for generating polarized light; 
  
 means for conveying the polarized light to a target; 
  
 a collector for receiving light reflected from the target; 
  
 a detector responsive to said collector for generating images at both parallel and perpendicular polarizations for each of a plurality of wavelengths;

  
 a range finder for detecting a distance to the target; and

  
 control electronics for controlling the generating of images
and the range finder. 
  
 20. The apparatus of claim 19 wherein either said light
source or said detector is wavelength tunable. 
  
 21. The apparatus of claim 19
wherein said detector includes a charge coupled device. 
  
 22. The apparatus of
claim 19 wherein said light source includes a monochromator. 
  
 23. The apparatus
of claim 19 wherein said light source or said detector includes an AOTF. 
  
 24.
The apparatus of claim 19 wherein said light source includes a polarizing element in series with a source of illumination. 
  
 25. The apparatus of claim 19 wherein said range finder includes either an optical, acoustical or mechanical device. 
  
 26. The apparatus of claim 19 wherein said range finder comprises: 
  
 a light source for generating a collimated beam of known diameter and degree
of collimation for illuminating a spot of said target; and 
  
 a
collector for detecting and recording the size of the illuminated spot reflected from said target; 
  
 wherein said control electronics calculates the distance to said target using the size of the illuminated spot and the known diameter and degree of
collimation of the beam. 
  

 25 

 27. An apparatus, comprising: 
  
 a light source for generating polarized light; 
  
 a first fiber optic path having a proximal end responsive to said light source and a distal end having an illumination port for illuminating a target;

  
 a second fiber optic path having a distal end having an
imaging port responsive to light reflected by the target and a proximal end, said first and second fiber optic paths constructed such that said distal ends can be inserted into a body cavity; 
  
 a detector responsive to said proximal end of said second fiber optic path
for generating images at both parallel and perpendicular polarizations for each of a plurality of wavelengths; 
  
 a range finder for detecting a distance from said distal ends of said fiber optic paths to the target; and 
  
 control electronics for controlling the generating of images and the range
finder. 
  
 28. The apparatus of claim 27 wherein either said light source or said
detector is wavelength tunable. 
  
 29. The apparatus of claim 27 wherein said
detector includes a charge coupled device. 
  
 30. The apparatus of claim 27
wherein said light source includes a monochromator. 
  
 31. The apparatus of claim
27 wherein said light source or said detector includes an AOTF. 
  
 32. The
apparatus of claim 27 wherein said light source includes a polarizing element in series with a source of illumination. 
  
 33. The apparatus of claim 27 wherein said range finder includes either an optical, acoustical or mechanical device. 
  
 34. The apparatus of claim 27 wherein said range finder comprises: 
  
 a light source for generating a collimated beam of known diameter and degree
of collimation for illuminating a spot of said target; and 
  
 a
collector for detecting and recording the size of the illuminated spot reflected from said target; 
  
 wherein said control electronics calculates the distance from said distal ends of said fiber optic paths to said target using the size of the illuminated
spot and the known diameter and degree of collimation of the beam. 
  
 35. A
system, comprising: 
  
 a light source for generating polarized
light; 
  
 means for conveying the polarized light to a target;

  
 a collector for receiving light reflected from the target;

  
 a detector responsive to said collector for generating images
at both parallel and perpendicular polarizations for each of a plurality of wavelengths; 
  
 a range finder for detecting a distance to the target; 
  
 control electronics for controlling the generation of the images and distance detection; and 
  
 an analyzer for analyzing the images based on the detected distance. 
  
 36. The system of claim 35 wherein either said light source or said detector is wavelength tunable under the control of said control
electronics. 
  
 37. The system of claim 35 wherein said detector includes a
charge coupled device under the control of said control electronics. 
  

 26 

 ABSTRACT 
  
 An apparatus for image elastic scattering spectroscopy is disclosed that is comprised of a light source for generating polarized light. Means are provided
to convey the polarized light to a target. A collector receives light reflected from the target. A detector is responsive to the collector for generating images at both parallel and perpendicular polarizations for each of a plurality of wavelengths.
A range finder detects a distance to the target. Control electronics control the image generation and the range finder. The apparatus may be configured to image areas on the surface of the body or configured so as to be inserted into various body
cavities. Typically, the apparatus will be used in conjunction with an analyzer for analyzing the images for evidence of abnormal cells. Methods of gathering data and of screening for abnormal cells are also disclosed. 
  

 27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]